References
1. Farrell B, Raman-Wilms L, Sadowski CA, Mallery L, Turner J, Gagnon C, et al. A Proposed Curricular Framework for an Interprofessional Approach to Deprescribing. Med Sci Educ. 2023;33(2):551-67.
2. Guyatt GH, Alonso-Coello P, Schünemann HJ, Djulbegovic B, Nothacker M, Lange S, et al. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J Clin Epidemiol. 2016;80:3-7.
3. Leitch S, Dovey SM, Cunningham WK, Smith AJ, Zeng J, Reith DM, et al. Medication-related harm in New Zealand general practice: a retrospective records review. Br J Gen Pract. 2021;71(709):e626-e33.
4. Ong KY, Lee PSS, Lee ES. Patient-centred and not disease-focused: a review of guidelines and multimorbidity. Singapore Med J. 2020;61(11):584-90.
5. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716-24.
6. El Masri H, McGuire TM, van Driel ML, Benham H, Hollingworth SA. Dynamics of Patient-Based Benefit-Risk Assessment of Medicines in Chronic Diseases: A Systematic Review. Patient Prefer Adherence. 2022;16:2609-37.
7. O'Mahony D, Gallagher PF. Inappropriate prescribing in the older population: need for new criteria. Age Ageing. 2008;37(2):138-41.
8. Opondo D, Eslami S, Visscher S, de Rooij SE, Verheij R, Korevaar JC, et al. Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review. PLoS One. 2012;7(8):e43617.
9. Alhawassi TM, Alatawi W, Alwhaibi M. Prevalence of potentially inappropriate medications use among older adults and risk factors using the 2015 American Geriatrics Society Beers criteria. BMC Geriatr. 2019;19(1):154.
10. Tian F, Chen Z, Zeng Y, Feng Q, Chen X. Prevalence of Use of Potentially Inappropriate Medications Among Older Adults Worldwide: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2023;6(8):e2326910.
11. Sönnerstam E, Sjölander M, Gustafsson M. An evaluation of the prevalence of potentially inappropriate medications in older people with cognitive impairment living in Northern Sweden using the EU(7)-PIM list. Eur J Clin Pharmacol. 2017;73(6):735-42.
12. Xing XX, Zhu C, Liang HY, Wang K, Chu YQ, Zhao LB, et al. Associations Between Potentially Inappropriate Medications and Adverse Health Outcomes in the Elderly: A Systematic Review and Meta-analysis. Ann Pharmacother. 2019;53(10):1005-19.
13. Lu WH, Wen YW, Chen LK, Hsiao FY. Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study. CMAJ. 2015;187(4):E130-e7.
14. Malakouti SK, Javan-Noughabi J, Yousefzadeh N, Rezapour A, Mortazavi SS, Jahangiri R, et al. A Systematic Review of Potentially Inappropriate Medications Use and Related Costs Among the Elderly. Value in Health Regional Issues. 2021;25:172-9.
15. Moon A, Jang S, Kim JH, Jang S. Risk of falls or fall-related injuries associated with potentially inappropriate medication use among older adults with dementia. BMC Geriatr. 2024;24(1):699.
16. O'Donnell LK, Langford A. Should we deprescribe the term "deprescribing"? BMJ. 2024;386:q2007.
17. Australia TRACoGPaO. Referring to other medical specialists: A guide for ensuring good referral outcomes for your patients. 2nd ed. East Melbourne, Vic: RACGP; 2019.
18. Page A, Clifford R, Potter K, Etherton-Beer C. A concept analysis of deprescribing medications in older people. J Pharm Pract Res. 2018;48(2):132-48.
19. Ekman I, Swedberg K, Taft C, Lindseth A, Norberg A, Brink E, et al. Person-centered care--ready for prime time. Eur J Cardiovasc Nurs. 2011;10(4):248-51.
20. Kogan AC, Wilber K, Mosqueda L. Person-Centered Care for Older Adults with Chronic Conditions and Functional Impairment: A Systematic Literature Review. J Am Geriatr Soc. 2016;64(1):e1-7.
21. Lines LM, Lepore M, Wiener JM. Patient-centered, Person-centered, and Person-directed Care: They are Not the Same. Med Care. 2015;53(7):561-3.
22. Smith H, Miller K, Barnett N, Oboh L, Jones E, Darcy C, et al. Person-Centred Care Including Deprescribing for Older People. Pharmacy (Basel). 2019;7(3).
23. Anker-Hansen C, Skovdahl K, McCormack B, Tønnessen S. The third person in the room: The needs of care partners of older people in home care services-A systematic review from a person-centred perspective. J Clin Nurs. 2018;27(7-8):e1309-e26.
24. Jansen J, Naganathan V, Carter SM, McLachlan AJ, Nickel B, Irwig L, et al. Too much medicine in older people? Deprescribing through shared decision making. BMJ. 2016;353:i2893.
25. Linsky A, Simon SR, Bokhour B. Patient perceptions of proactive medication discontinuation. Patient Educ Couns. 2015;98(2):220-5.
26. Moen J, Bohm A, Tillenius T, Antonov K, Nilsson JL, Ring L. "I don't know how many of these [medicines] are necessary.." - a focus group study among elderly users of multiple medicines. Patient Educ Couns. 2009;74(2):135-41.
27. Lau DT, Briesacher BA, Mercaldo ND, Halpern L, Osterberg EC, Jarzebowski M, et al. Older patients' perceptions of medication importance and worth: an exploratory pilot study. Drugs Aging. 2008;25(12):1061-75.
28. Molnar F, Frank CC. Optimizing geriatric care with the GERIATRIC 5Ms. Can Fam Physician. 2019;65(1):39.
29. NPS MedicineWise. Prescribing Competencies Framework Australia: NPS MedicineWise; 2024 [Available from: https://www.nps.org.au/prescribing-competencies-framework].
30. Djatche L, Lee S, Singer D, Hegarty SE, Lombardi M, Maio V. How confident are physicians in deprescribing for the elderly and what barriers prevent deprescribing? J Clin Pharm Ther. 2018;43(4):550-5.
31. Farrell B, Richardson L, Raman-Wilms L, de Launay D, Alsabbagh MW, Conklin J. Self-efficacy for deprescribing: A survey for health care professionals using evidence-based deprescribing guidelines. Res Social Adm Pharm. 2018;14(1):18-25.
32. Raman-Wilms L, Farrell B, Sadowski C, Austin Z. Deprescribing: An educational imperative. Research in Social and Administrative Pharmacy. 2019;15(6):790-5.
33. Todd A, Jansen J, Colvin J, McLachlan AJ. The deprescribing rainbow: a conceptual framework highlighting the importance of patient context when stopping medication in older people. BMC Geriatr. 2018;18(1):295.
34. Farrell B, Conklin J, Dolovich L, Irving H, Maclure M, McCarthy L, et al. Deprescribing guidelines: An international symposium on development, implementation, research and health professional education. Res Social Adm Pharm. 2019;15(6):780-9.
35. Primary Health Tasmania. Medication management – deprescribing Tasmania: Primary Health Tasmania; 2022 [cited 2023 11 November]. Available from: https://www.primaryhealthtas.com.au/resources/deprescribing-resources/.
36. NSW Therapeutic Advisory Group (NSW TAG). Deprescribing Tools New South Wales: NSW Therapeutic Advisory Group Inc.; 2021 [Available from: https://www.nswtag.org.au/deprescribing-tools/].
37. Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin PJ, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust. 2019;210(4):174-9.
38. Langford AV, Lin CC, Bero L, Blyth FM, Doctor J, Holliday S, et al. Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations. Med J Aust. 2023;219(2):80-9.
39. Pottie K, Thompson W, Davies S, Grenier J, Sadowski CA, Welch V, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339-51.
40. Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017;63(5):354-64.
41. Farrell B, Black C, Thompson W, McCarthy L, Rojas-Fernandez C, Lochnan H, et al. Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline. Can Fam Physician. 2017;63(11):832-43.
42. Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, McCarthy L, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(1):17-27.
43. Horowitz M, Taylor D. The Maudsley deprescribing guidelines : antidepressants, benzodiazepines, gabapentinoids and z-drugs. Hoboken, NJ; Wiley Blackwell; 2024.
44. Gillespie R, Mullan J, Harrison L. Factors which influence the deprescribing decisions of community-living older adults and GPs in Australia. Health Soc Care Community. 2022;30(6):e6206-e16.
45. Peat G, Fylan B, Marques I, Raynor DK, Breen L, Olaniyan J, et al. Barriers and facilitators of successful deprescribing as described by older patients living with frailty, their informal carers and clinicians: a qualitative interview study. BMJ Open. 2022;12(3):e054279.
46. McKinlay JB, Trachtenberg F, Marceau LD, Katz JN, Fischer MA. Effects of patient medication requests on physician prescribing behavior: results of a factorial experiment. Med Care. 2014;52(4):294-9.
47. Zechmann S, Trueb C, Valeri F, Streit S, Senn O, Neuner-Jehle S. Barriers and enablers for deprescribing among older, multimorbid patients with polypharmacy: an explorative study from Switzerland. BMC Fam Pract. 2019;20(1):64.
48. Linsky A, Zimmerman KM. Provider and System-Level Barriers to Deprescribing: Interconnected Problems and Solutions. Public Policy & Aging Report. 2018;28(4):129-33.
49. Kaas Oldenburg LI, Dalin D, Drastrup AM, Vermehren C. Deprescribing: What is the gold standard? Themes that characterized the discussions at the first Danish symposium on evidence-based deprescribing. Explor Res Clin Soc Pharm. 2022;5:100102.
50. Australian Institute of Health and Welfare. Older Australians Canberra: AIHW; 2023 [Available from: https://www.aihw.gov.au/reports/older-people/older-australians/contents/about].
51. Lim R, Ellett LMK, Semple S, Roughead EE. The Extent of Medication-Related Hospital Admissions in Australia: A Review from 1988 to 2021. Drug Saf. 2022;45(3):249-57.
52. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.
53. Page AT, Falster MO, Litchfield M, Pearson SA, Etherton-Beer C. Polypharmacy among older Australians, 2006-2017: a population-based study. Med J Aust. 2019;211(2):71-5.
54. Le Couteur DG, McLachlan AJ, Hilmer SN. Polypharmacy in older people: when should you deprescribe? Med Today. 2016;17:16-24.
55. Kuijpers MA, van Marum RJ, Egberts AC, Jansen PA. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2008;65(1):130-3.
56. Adair T, Ortega L, Temple J. Senior Australians and Prescription Medicines: Usage, Sources of Information and Affordability. Aging DoHa, editor. Canberra: National Seniors Productive Ageing Centre; 2012.
57. Gnjidic D, Cumming RG, Le Couteur DG, Handelsman DJ, Naganathan V, Abernethy DR, et al. Drug Burden Index and physical function in older Australian men. Br J Clin Pharmacol. 2009;68(1):97-105.
58. Roughead EE, Kalisch LM, Barratt JD, Gilbert AL. Prevalence of potentially hazardous drug interactions amongst Australian veterans. Br J Clin Pharmacol. 2010;70(2):252-7.
59. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. DICP. 1990;24(11):1093-7.
60. Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9(6):364-77.
61. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29-34.
62. Hilmer S. The dilemma of polypharmacy. Aust Prescr. 2008;31:2-3.
63. Garfinkel D, Ilhan B, Bahat G. Routine deprescribing of chronic medications to combat polypharmacy. Ther Adv Drug Saf. 2015;6(6):212-33.
64. Fortin M, Soubhi H, Hudon C, Bayliss EA, van den Akker M. Multimorbidity's many challenges. BMJ. 2007;334(7602):1016-7.
65. Qi K, Reeve E, Hilmer SN, Pearson SA, Matthews S, Gnjidic D. Older peoples' attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. Int J Clin Pharm. 2015;37(5):949-57.
66. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827-34.
67. Page AT, Potter K, Clifford R, McLachlan AJ, Etherton-Beer C. Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel. Intern Med J. 2016;46(10):1189-97.
68. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18):E839-42.
69. National Health and Medical Research Council (NHMRC). Procedures and requirements for meeting the 2011 NHMRC standard for clinical practice guidelines Canberra, Australian Capital Territory: NHMRC; 2011.
70. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2024 2024 [Available from: https://atcddd.fhi.no/atc_ddd_index/].
71. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94.
72. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6.
73. The GRADE Working Group. GRADE Handbook 2013 [Available from: https://gdt.gradepro.org/app/handbook/handbook.html].
74. Graves T, Hanlon JT, Schmader KE, Landsman PB, Samsa GP, Pieper CF, et al. Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med. 1997;157(19):2205-10.
75. Allard J, Hébert R, Rioux M, Asselin J, Voyer L. Efficacy of a clinical medication review on the number of potentially inappropriate prescriptions prescribed for community-dwelling elderly people. CMAJ. 2001;164(9):1291-6.
76. Balsom C, Pittman N, King R, Kelly D. Impact of a pharmacist-administered deprescribing intervention on nursing home residents: a randomized controlled trial. Int J Clin Pharm. 2020;42(4):1153-67.
77. Bayliss EA, Shetterly SM, Drace ML, Norton JD, Maiyani M, Gleason KS, et al. Deprescribing Education vs Usual Care for Patients With Cognitive Impairment and Primary Care Clinicians: The OPTIMIZE Pragmatic Cluster Randomized Trial. JAMA Intern Med. 2022;182(5):534-42.
78. Beer C, Loh PK, Peng YG, Potter K, Millar A. A pilot randomized controlled trial of deprescribing. Ther Adv Drug Saf. 2011;2(2):37-43.
79. Cateau D, Ballabeni P, Niquille A. Effects of an interprofessional deprescribing intervention in Swiss nursing homes: the Individual Deprescribing Intervention (IDeI) randomised controlled trial. BMC Geriatr. 2021;21(1):655.
80. Cossette B, Ethier J-F, Joly-Mischlich T, Bergeron J, Ricard G, Brazeau S, et al. Reduction in targeted potentially inappropriate medication use in elderly inpatients: a pragmatic randomized controlled trial. Eur J Clin Pharmacol. 2017;73(10):1237-45.
81. Curtin D, Jennings E, Daunt R, Curtin S, Randles M, Gallagher P, et al. Deprescribing in Older People Approaching End of Life: A Randomized Controlled Trial Using STOPPFrail Criteria. J Am Geriatr Soc. 2020;68(4):762-9.
82. Dalleur O, Boland B, Losseau C, Henrard S, Wouters D, Speybroeck N, et al. Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: a randomised controlled study. Drugs Aging. 2014;31(4):291-8.
83. Etherton-Beer C, Page A, Naganathan V, Potter K, Comans T, Hilmer SN, et al. Deprescribing to optimise health outcomes for frail older people: a double-blind placebo-controlled randomised controlled trial-outcomes of the Opti-med study. Age Ageing. 2023;52(5).
84. Gnjidic D, Le Couteur DG, Abernethy DR, Hilmer SN. A pilot randomized clinical trial utilizing the drug burden index to reduce exposure to anticholinergic and sedative medications in older people. Ann Pharmacother. 2010;44(11):1725-32.
85. Hanlon JT, Weinberger M, Samsa GP, Schmader KE, Uttech KM, Lewis IK, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996;100(4):428-37.
86. Jamieson H, Nishtala PS, Bergler HU, Weaver SK, Pickering JW, Ailabouni NJ, et al. Deprescribing anticholinergic and sedative drugs to reduce polypharmacy in frail older adults living in the community: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2023.
87. Kouladjian O'Donnell L, Sawan M, Hilmer SN, Reeve E, Chen TF, Gnjidic D, et al. Impact of the Goal-directed Medication Review Electronic Decision Support System on Drug Burden Index: A cluster-randomised clinical trial in primary care. Br J Clin Pharmacol. 2021;87(3):1499-511.
88. Kua C-H, Yeo CYY, Leong IY-O, Tan PC, Char CWT, Tan CWY, et al. Association of Deprescribing With Reduction in Mortality and Hospitalization: A Pragmatic Stepped-Wedge Cluster-Randomized Controlled Trial. J Am Med Dir Assoc. 2021;22(1):82.
89. Mahlknecht A, Wiedermann CJ, Sandri M, Engl A, Valentini M, Vögele A, et al. Expert-based medication reviews to reduce polypharmacy in older patients in primary care: a northern-Italian cluster-randomised controlled trial. BMC Geriatr. 2021;21(1):659.
90. Phelan EA, Williamson BD, Balderson BH, Cook AJ, Piccorelli AV, Fujii MM, et al. Reducing Central Nervous System-Active Medications to Prevent Falls and Injuries Among Older Adults: A Cluster Randomized Clinical Trial. JAMA Netw Open. 2024;7(7):e2424234.
91. Pitkälä KH, Juola AL, Kautiainen H, Soini H, Finne-Soveri UH, Bell JS, et al. Education to reduce potentially harmful medication use among residents of assisted living facilities: a randomized controlled trial. J Am Med Dir Assoc. 2014;15(12):892-8.
92. Potter K, Flicker L, Page A, Etherton-Beer C. Deprescribing in Frail Older People: A Randomised Controlled Trial. PLoS One. 2016;11(3):e0149984.
93. Rieckert A, Reeves D, Altiner A, Drewelow E, Esmail A, Flamm M, et al. Use of an electronic decision support tool to reduce polypharmacy in elderly people with chronic diseases: cluster randomised controlled trial. BMJ (Clinical research ed). 2020;369(8900488, bmj, 101090866):m1822.
94. Rudolf H, Thiem U, Aust K, Krause D, Klaaßen-Mielke R, Greiner W, et al. Reduction of Potentially Inappropriate Medication in the Elderly. Dtsch Arztebl Int. 2021;118(51-52):875-82.
95. Van Der Meer HG, Wouters H, Pont LG, Taxis K. Reducing the anticholinergic and sedative load in older patients on polypharmacy by pharmacist-led medication review: A randomised controlled trial. BMJ Open. 2018;8(7).
96. Vasilevskis EE, Shah AS, Hollingsworth EK, Shotwell MS, Kripalani S, Mixon AS, et al. Deprescribing Medications Among Older Adults From End of Hospitalization Through Postacute Care: A Shed-MEDS Randomized Clinical Trial. JAMA Intern Med. 2023;183(3):223-31.
97. Weber V, White A, McIlvried R. An electronic medical record (EMR)-based intervention to reduce polypharmacy and falls in an ambulatory rural elderly population. J Gen Intern Med. 2008;23(4):399-404.
98. Wong APY, Ting TW, Charissa EJM, Boon TW, Heng KY, Leng LL. Feasibility & Efficacy of Deprescribing rounds in a Singapore rehabilitative hospital- a randomised controlled trial. BMC Geriatr. 2021;21(1):584.
99. Zechmann S, Senn O, Valeri F, Essig S, Merlo C, Rosemann T, et al. Effect of a patient-centred deprescribing procedure in older multimorbid patients in Swiss primary care - A cluster-randomised clinical trial. BMC Geriatr. 2020;20(1):471.
100. Bawazeer G, Alsaad S, Almalag H, Alqahtani A, Altulaihi N, Alodhayani A, et al. Impact of Specialized Clinics on Medications Deprescribing in Older Adults: A Pilot Study in Ambulatory Care Clinics in a Teaching Hospital. Saudi Pharm J. 2022;30(7):1027-35.
101. Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J. 2007;9(6):430-4.
102. Komagamine J, Hagane K. Intervention to improve the appropriate use of polypharmacy for older patients with hip fractures: an observational study. BMC Geriatr. 2017;17(1):288.
103. Russell P, Hewage U, McDonald C, Thompson C, Woodman R, Mangoni AA. Prospective cohort study of nonspecific deprescribing in older medical inpatients being discharged to a nursing home. Ther Adv Drug Saf. 2021;12:20420986211052344.
104. Van der Linden L, Decoutere L, Walgraeve K, Milisen K, Flamaing J, Spriet I, et al. Combined Use of the Rationalization of Home Medication by an Adjusted STOPP in Older Patients (RASP) List and a Pharmacist-Led Medication Review in Very Old Inpatients: Impact on Quality of Prescribing and Clinical Outcome. Drugs Aging. 2017;34(2):123-33.
105. Yeh YC, Liu CL, Peng LN, Lin MH, Chen LK. Potential benefits of reducing medication-related anticholinergic burden for demented older adults: a prospective cohort study. Geriatr Gerontol Int. 2013;13(3):694-700.
106. Garfinkel D. Poly-de-prescribing to treat polypharmacy: efficacy and safety. Ther Adv Drug Saf. 2018;9(1):25-43.
107. Garfinkel D, Levy Y. Optimizing clinical outcomes in polypharmacy through poly-de-prescribing: a longitudinal study. Front Med (Lausanne). 2024;11:1365751.
108. Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170(18):1648-54.
109. Gerety MB, Cornell JE, Plichta DT, Eimer M. Adverse events related to drugs and drug withdrawal in nursing home residents. J Am Geriatr Soc. 1993;41(12):1326-32.
110. Hurley E, Dalton K, Byrne S, Foley T, Walsh E. Pharmacist-Led Deprescribing Using STOPPFrail for Frail Older Adults in Nursing Homes. J Am Med Dir Assoc. 2024;25(9):105122.
111. Jovevski JJ, Smith CR, Roberts JL, Dev S, Iloabuchi TC, Gruber EA, et al. Implementation of a compulsory clinical pharmacist-led medication deprescribing intervention in high-risk seniors in the emergency department. Acad Emerg Med. 2023;30(4):410-9.
112. Etherton-Beer C, Page A, Criddle D, Somers G, Parkinson L, Clifford R, et al. The Australian Team Approach to Polypharmacy Evaluation and Reduction (AusTAPER) hospital study: effect of a collaborative medication review on the number of current regular medicines for older hospital inpatients. Intern Med J. 2024;54(10):1719-32.
113. McDonald EG, Wu PE, Rashidi B, Wilson MG, Bortolussi-Courval É, Atique A, et al. The MedSafer Study-Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial. JAMA Intern Med. 2022;182(3):265-73.
114. McDonald EG, Wu PE, Rashidi B, Forster AJ, Huang A, Pilote L, et al. The MedSafer Study: A Controlled Trial of an Electronic Decision Support Tool for Deprescribing in Acute Care. J Am Geriatr Soc. 2019;67(9):1843-50.
115. Campbell AJ, Robertson MC, Gardner MM, Norton RN, Buchner DM. Psychotropic medication withdrawal and a home-based exercise program to prevent falls: a randomized, controlled trial. J Am Geriatr Soc. 1999;47(7):850-3.
116. Mott DA, Martin B, Breslow R, Michaels B, Kirchner J, Mahoney J, et al. Impact of a medication therapy management intervention targeting medications associated with falling: Results of a pilot study. J Am Pharm Assoc (2003). 2016;56(1):22-8.
117. Selman K, Roberts E, Niznik J, Anton G, Kelley C, Northam K, et al. Initiative to deprescribe high-risk drugs for older adults presenting to the emergency department after falls. J Am Geriatr Soc. 2024;72 Suppl 3:S60-s7.
118. Pavon JM, Davidson S, Sloane R, Pepin M, Bryan W, Bailey J, et al. Deprescribing electronic case reviews for older veterans at risk for falls: Effects on drug burden and falls. J Am Geriatr Soc. 2024;72(2):433-43.
119. Salonoja M, Salminen M, Vahlberg T, Aarnio P, Kivelä SL. Withdrawal of psychotropic drugs decreases the risk of falls requiring treatment. Arch Gerontol Geriatr. 2012;54(1):160-7.
120. Seto H, Ishimaru N, Ohnishi J, Kanzawa Y, Nakajima T, Shimokawa T, et al. Multidisciplinary Team Deprescribing Intervention for Polypharmacy in Elderly Orthopedic Inpatients: A Propensity Score-matched Analysis of a Retrospective Cohort Study. Intern Med. 2022;61(16):2417-26.
121. van der Velde N, Stricker BH, Pols HA, van der Cammen TJ. Withdrawal of fall-risk-increasing drugs in older persons: effect on mobility test outcomes. Drugs Aging. 2007;24(8):691-9.
122. Haque R, Alavi Z. Assessing the Impact of an Interdisciplinary Team Approach Using the ARMOR Protocol on the Rate of Psychotropic Medications and Other Quality Indicators in Long-Term Care Facilities. Annals of Long Term Care. 2019;27(5):24-31.
123. Leguelinel-Blache G, Castelli C, Rolain J, Bouvet S, Chkair S, Kabani S, et al. Impact of pharmacist-led multidisciplinary medication review on the safety and medication cost of the elderly people living in a nursing home: a before-after study. Expert Rev Pharmacoecon Outcomes Res. 2020;20(5):481-90.
124. Edey R, Edwards N, Von Sychowski J, Bains A, Spence J, Martinusen D. Impact of deprescribing rounds on discharge prescriptions: an interventional trial. Int J Clin Pharm. 2019;41(1):159-66.
125. Herrinton LJ, Lo K, Alavi M, Alexeeff SE, Butler KM, Chang C, et al. Effectiveness of Bundled Hyperpolypharmacy Deprescribing Compared With Usual Care Among Older Adults: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(7):e2322505.
126. Lee JW, Hollingsworth EK, Shah AS, Szanton SL, Perrin N, Mixon AS, et al. Emergency department visits and hospital readmissions after a deprescribing intervention among hospitalized older adults. J Am Geriatr Soc. 2024;72(7):2038-47.
127. McCarthy C, Clyne B, Corrigan D, Boland F, Wallace E, Moriarty F, et al. Supporting prescribing in older people with multimorbidity and significant polypharmacy in primary care (SPPiRE): a cluster randomised controlled trial protocol and pilot. Implementation science : IS. 2017;12(1):99.
128. Mortsiefer A, Löscher S, Pashutina Y, Santos S, Altiner A, Drewelow E, et al. Family Conferences to Facilitate Deprescribing in Older Outpatients With Frailty and With Polypharmacy: The COFRAIL Cluster Randomized Trial. JAMA Netw Open. 2023;6(3):e234723.
129. McCarthy C, Clyne B, Boland F, Moriarty F, Flood M, Wallace E, et al. GP-delivered medication review of polypharmacy, deprescribing, and patient priorities in older people with multimorbidity in Irish primary care (SPPiRE Study): A cluster randomised controlled trial. PLoS Med. 2022;19(1):e1003862.
130. Anderson K, Freeman C, Foster M, Scott I. GP-Led Deprescribing in Community-Living Older Australians: An Exploratory Controlled Trial. J Am Geriatr Soc. 2020;68(2):403-10.
131. Kose E, Matsumoto A, Yoshimura Y. Association between deprescribing from polypharmacy and functional recovery and home discharge among older patients with sarcopenia after stroke. Nutrition. 2023;111:112040.
132. Ye S, Boyko S, Patel M, Shah K, Turbow S, Ohuabunwa U. Deprescribing Medications Among Older People to Reduce Polypharmacy at a Comprehensive Academic Medical Center. The Senior care pharmacist. 2021;36(4):208-16.
133. Adeola M, Azad R, Liebl M, Kassie GM, Shirkey B, Taffet G, et al. Multicomponent Interventions Reduce High-Risk Medications for Delirium in Hospitalized Older Adults. J Am Geriatr Soc. 2018;66(8):1638-45.
134. Hopkins AM, Lerner K, Grinich E, Ahn J, Choi Y, Hanifin J, et al. The Frequency and Utility of Drug Cessation Trials in Older Adults With Chronic Eczematous Dermatitis of Unknown Etiology: A Retrospective Cohort Study. Dermatitis. 2023;34(5):419-24.
135. Husebø BS, Ballard C, Aarsland D, Selbaek G, Slettebo DD, Gulla C, et al. The Effect of a Multicomponent Intervention on Quality of Life in Residents of Nursing Homes: A Randomized Controlled Trial (COSMOS). J Am Med Dir Assoc. 2019;20(3):330-9.
136. Etherton-Beer C, Page A, Naganathan V, Potter K, Comans T, Hilmer SN, et al. Deprescribing to optimise health outcomes for frail older people: a double-blind placebo-controlled randomised controlled trial-outcomes of the Opti-med study. Age Ageing. 2023;52(5):afad081.
137. Cossette B, Boissy P, Milot M-H, Hilmer SN, Kouladjian O'donnell L, Gnjidic D, et al. Feasibility of Measuring Physical Function by Wearable Devices During Deprescribing of Anticholinergic and Sedative Medicatiossns. Can J Aging. 2025:1-8.
138. Ailabouni N, Mangin D, Nishtala PS. DEFEAT-polypharmacy: deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities. Int J Clin Pharm. 2019;41(1):167-78.
139. Wehran T, Eidam A, Czock D, Kopitz J, Plaschke K, Mattern M, et al. Development and Pilot Testing of an Algorithm-Based Approach to Anticholinergic Deprescribing in Older Patients. Drugs Aging. 2024;41(2):153-64.
140. BoyÉ NDA, Van Der Velde N, De Vries OJ, Van Lieshout EMM, Hartholt KA, Mattace-Raso FUS, et al. Effectiveness of medication withdrawal in older fallers: results from the Improving Medication Prescribing to reduce Risk Of FALLs (IMPROveFALL) trial. Age Ageing. 2017;46(1):142-6.
141. Gillespie P, Moriarty F, Smith SM, Hobbins A, Walsh S, Clyne B, et al. Cost effectiveness of a GP delivered medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care: the SPPiRE cluster randomised controlled trial. Eur J Health Econ. 2025;26(3):427-54.
142. Moga DC, Abner EL, Rigsby DN, Eckmann L, Huffmyer M, Murphy RR, et al. Optimizing medication appropriateness in older adults: a randomized clinical interventional trial to decrease anticholinergic burden. Alzheimers Res Ther. 2017;9(1):36.
143. Choosing Wisely Canada. Toolkit: Bye-Bye, PPI 2017 [Available from: https://choosingwiselycanada.org/toolkit/bye-bye-ppi/].
144. Liu Y, Zhu X, Li R, Zhang J, Zhang F. Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study. BMJ Open. 2020;10(11):e040473.
145. Koggel LM, Lantinga MA, Büchner FL, Drenth JPH, Frankema JS, Heeregrave EJ, et al. Predictors for inappropriate proton pump inhibitor use: observational study in primary care. Br J Gen Pract. 2022;72(725):e899-e906.
146. Rane PP, Guha S, Chatterjee S, Aparasu RR. Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Social Adm Pharm. 2017;13(2):358-63.
147. Boghossian TA, Rashid FJ, Thompson W, Welch V, Moayyedi P, Rojas-Fernandez C, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;3(3):Cd011969.
148. Schepisi R, Fusco S, Sganga F, Falcone B, Vetrano DL, Abbatecola A, et al. Inappropriate Use of Proton Pump Inhibitors in Elderly Patients Discharged from Acute Care Hospitals. J Nutr Health Aging. 2016;20(6):665-70.
149. Pratt NL, Kalisch Ellett LM, Sluggett JK, Gadzhanova SV, Ramsay EN, Kerr M, et al. Use of proton pump inhibitors among older Australians: national quality improvement programmes have led to sustained practice change. Int J Qual Health Care. 2017;29(1):75-82.
150. Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut. 2022;71(1):16.
151. Ma YJ, Cao ZX, Li Y, Feng SY. Proton pump inhibitor use increases hepatic encephalopathy risk: A systematic review and meta-analysis. World J Gastroenterol. 2019;25(21):2675-82.
152. Maideen NMP. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Med J. 2023;59(2):115-27.
153. Northuis CA, Bell EJ, Lutsey PL, George KM, Gottesman RF, Mosley TH, et al. Cumulative Use of Proton Pump Inhibitors and Risk of Dementia. Neurology. 2023;101(18):e1771-e8.
154. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019;157(3):682-91.e2.
155. Yang M, He Q, Gao F, Nirantharakumar K, Veenith T, Qin X, et al. Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials. BMC Med. 2021;19(1):316.
156. Xia B, He Q, Smith FG, Gkoutos VG, Nirantharakumar K, Kuo ZC, et al. Individualized prevention of proton pump inhibitor related adverse events by risk stratification. Nature Communications. 2024;15(1):3591.
157. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8(12):e80633.
158. Rafhi E, Stupans I, Stevens JE, Soo Park J, Wang KN. The influence of beliefs and health literacy on medication-related outcomes in older adults: A cross-sectional study. Research in Social and Administrative Pharmacy. 2025;21(1):47-55.
159. Turner J, Thompson W, Reeve E, Bell J. Deprescribing proton pump inhibitors. Aust J Gen Pract. 2022;51:845-8.
160. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-38.
161. Abrignani MG, Lombardo A, Braschi A, Renda N, Abrignani V. Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view. World J Cardiol. 2023;15(8):375-94.
162. Kanno T, Moayyedi P. Who Needs Gastroprotection in 2020? Curr Treat Options Gastroenterol. 2020;18(4):557-73.
163. Haghbin H, Zakirkhodjaev N, Husain FF, Lee-Smith W, Aziz M. Risk of Gastrointestinal Bleeding with Concurrent Use of NSAID and SSRI: A Systematic Review and Network Meta-Analysis. Dig Dis Sci. 2023;68(5):1975-82.
164. Bhardwaj S, Garvin S, Kuehl S, Van Epps J, Dunkerson F, Lehmann M, et al. Incorporation of Student Pharmacists into a Proton Pump Inhibitor Deprescribing Telehealth Program for Rural Veterans. Innov Pharm. 2022;13(3).
165. Calvo LLJ, García Cámara P, Llorente Barrio M, Sierra Gabarda O, Monzón Baez R, Arbonés Mainar JM, et al. Successful deprescribing of proton pump inhibitors with a patient-centered process: the DESPIBP Project. Eur J Clin Pharmacol. 2021;77(12):1927-33.
166. Czikk D, Parpia Y, Roberts K, Jain G, Vu DC, Zimmerman D. De-Prescribing Proton Pump Inhibitors in Patients With End Stage Kidney Disease: A Quality Improvement Project. Can J Kidney Health Dis. 2022;9:20543581221106244.
167. Lee C, Lo A, Ubhi K, Milewski M. Outcome after discontinuation of proton pump inhibitors at a residential care site: Quality improvement project. Can J Hosp Pharm. 2017;70(3):215-23.
168. Leszcynski L, Bente J. Development and Implementation of a Pharmacist-Led Proton Pump Inhibitor Deprescribing Algorithm in a Geriatric Ambulatory Office. Sr Care Pharm. 2023;38(3):105-12.
169. Linsky AM, Kressin NR, Stolzmann K, Pendergast J, Rosen AK, Bokhour BG, et al. Direct-to-consumer strategies to promote deprescribing in primary care: a pilot study. BMC Prim Care. 2022;23(1):53.
170. McDonald EG, Jones J, Green L, Jayaraman D, Lee TC. Reduction of inappropriate exit prescriptions for proton pump inhibitors: A before-after study using education paired with a web-based quality-improvement tool. J Hosp Med. 2015;10(5):281-6.
171. Reeve E, Andrews JM, Wiese MD, Hendrix I, Roberts MS, Shakib S. Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors. Ann Pharmacother. 2015;49(1):29-38.
172. Tandun R, Bubbar C, Tejani AM. Who has the guts to deprescribe proton pump inhibitors? A pharmacist-led intervention in a long-term care facility setting. Aging Medicine. 2019;2(2):112-7.
173. Visser AGR, Schols J, Prevoo M, Janknegt R, Winkens B. Deprescribing Statins and Proton Pump Inhibitors in Nursing Home Residents; a Pragmatic Exploratory Study. Gerontol Geriatr Med. 2021;7:23337214211050807.
174. Wahking RA, Steele RL, Hanners RE, Lockwood SM, Davis KW. Outcomes From a Pharmacist - led Proton Pump Inhibitor Stewardship Program at a Single Institution. Hosp Pharm. 2018;53(1):59-67.
175. Mati E, Mioux L, Ollagnier G, Waissi A, Benzerdjeb N, Messaoudi K, et al. How could proton pump inhibitors de-prescription be managed in geriatric long-term care? Therapie. 2024;79(6):699-708.
176. Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005;21(2):149-54.
177. Australian Medicines Handbook [Online]. Adelaide: Australian Medicines Handbook Pty Ltd; 2023 [updated July 2023. Available from: https://amhonline.amh.net.au/.
178. Therapeutic Guidelines. Benign Paroxysmal Positional Vertigo Melbourne: Therapeutic Guidelines Limited; 2017 [Available from: https://www.tg.org.au/].
179. By the American Geriatrics Society Beers Criteria® Update Expert P. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-81.
180. Athavale A, Athavale T, Roberts DM. Antiemetic drugs: what to prescribe and when. Aust Prescr. 2020;43(2):49-56.
181. Caughey GE, Roughead EE, Pratt N, Shakib S, Vitry AI, Gilbert AL. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? Pharmacoepidemiol Drug Saf. 2010;19(9):977-82.
182. Schuster BG, Kosar L, Kamrul R. Constipation in older adults: stepwise approach to keep things moving. Can Fam Physician. 2015;61(2):152-8.
183. Therapeutic Guidelines. Functional constipation in adults Melbourne: Therapeutic Guidelines Limited; 2022 [Available from: https://www.tg.org.au/].
184. Puga AM, Lopez-Oliva S, Trives C, Partearroyo T, Varela-Moreiras G. Effects of Drugs and Excipients on Hydration Status. Nutrients. 2019;11(3).
185. Australian Medicines Handbook [Online]. Adelaide: Australian Medicines Handbook Pty Ltd; 2025 [updated January 2025. Available from: https://amhonline.amh.net.au/.
186. Lyseng-Williamson KA. Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use. Drugs & Therapy Perspectives. 2018;34(7):300-10.
187. Aziz I, Whitehead WE, Palsson OS, Törnblom H, Simrén M. An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation. Expert Rev Gastroenterol Hepatol. 2020;14(1):39-46.
188. Therapeutic Guidelines. Opioid-induced constipation in adults Melbourne: Therapeutic Guidelines Limited; 2022 [Available from: https://www.tg.org.au/].
189. Captieux M, Fleetwood K, Kennon B, Sattar N, Lindsay R, Guthrie B, et al. Epidemiology of type 2 diabetes remission in Scotland in 2019: A cross-sectional population-based study. PLoS Med. 2021;18(11):e1003828.
190. Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 2015;175(3):356-62.
191. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419-30.
192. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59.
193. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in Diabetes. Diabetes Care. 2003;26(6):1902-12.
194. Anno T, Kaneto H, Shigemoto R, Kawasaki F, Kawai Y, Urata N, et al. Hypoinsulinemic hypoglycemia triggered by liver injury in elderly subjects with low body weight: case reports. Endocrinology, diabetes & metabolism case reports. 2018;2018(1):1-5.
195. Abdelhafiz AH, Rodríguez-Mañas L, Morley JE, Sinclair AJ. Hypoglycemia in older people - a less well recognized risk factor for frailty. Aging Dis. 2015;6(2):156-67.
196. Bradley MD, Arnold ME, Biskup BG, Campbell TM, 2nd, Fuhrman J, Guthrie GE, et al. Medication Deprescribing Among Patients With Type 2 Diabetes: A Qualitative Case Series of Lifestyle Medicine Practitioner Protocols. Clin Diabetes. 2023;41(2):163-76.
197. Weinstock RS, Aleppo G, Bailey TS, Bergenstal RM, Fisher WA, Greenwood DA, et al. ADA Clinical Compendia Series. The Role of Blood Glucose Monitoring in Diabetes Management. Arlington (VA): American Diabetes Association
© 2020 by American Diabetes Association. All rights reserved. None of the contents may be reproduced without the written permission of the American Diabetes Association.; 2020.
198. HbA1c and monitoring glycaemia. Aust J Gen Pract. 2012;41:37-40.
199. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
200. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359(15):1577-89.
201. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008;358(24):2545-59.
202. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008;358(24):2560-72.
203. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009;360(2):129-39.
204. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 13. Older Adults: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S216-s29.
205. Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med. 2018;168(8):569-76.
206. Westall SJ, Narayanan RP, Watmough S, Irving G, Furlong N, McNulty S, et al. The individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review. Clin Med (Lond). 2022;22(3):257-65.
207. Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(5):495-502.
208. Zinman B, Wanner C, Lachin John M, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28.
209. The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117-27.
210. The EMPA-KIDNEY Collaborative Group. Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2024;0(0).
211. Neal B, Perkovic V, Mahaffey KW, Zeeuw Dd, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-57.
212. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-306.
213. Nguyen TN, Yu J, Perkovic V, Jardine M, Mahaffey KW, Chow CK, et al. The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials. J Am Geriatr Soc. 2025.
214. Sinclair AJ, Abdelhafiz AH. The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required. Metabolites. 2025;15(1).
215. Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15-28.
216. Lincoff AM, Brown-Frandsen K, Colhoun Helen M, Deanfield J, Emerson Scott S, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-32.
217. Perkovic V, Tuttle Katherine R, Rossing P, Mahaffey Kenneth W, Mann Johannes FE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-21.
218. Hui RL, Chang CC, Niu F, Tang YK, Harano D, Deguzman L, et al. Evaluation of a Pharmacist-Managed Antidiabetic Deprescribing Program in an Integrated Health Care System. J Manag Care Spec Pharm. 2019;25(8):927-34.
219. Niznik JD, Zhao X, Slieanu F, Mor MK, Aspinall SL, Gellad WF, et al. Effect of Deintensifying Diabetes Medications on Negative Events in Older Veteran Nursing Home Residents. Diabetes Care. 2022;45(7):1558-67.
220. Silverii GA, Caldini E, Dicembrini I, Mannucci E, Pieri M, Monami M. Deprescription in elderly patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2020;170((Silverii, Caldini, Dicembrini, Mannucci) University of Florence, Viale Morgagni, Firenze 50 - 50134, Italy(Pieri, Monami) Careggi Hospital, Diabetology Unit, Largo Brambilla, Firenze 3 - 50134, Italy):108498.
221. Sjöblom P, AndersTengblad, Löfgren UB, Lannering C, Anderberg N, Rosenqvist U, et al. Can diabetes medication be reduced in elderly patients? An observational study of diabetes drug withdrawal in nursing home patients with tight glycaemic control. Diabetes Res Clin Pract. 2008;82(2):197-202.
222. Adamczak M, Chudek J, Zejda J, Bartmańska M, Grodzicki T, Zdrojewski T, et al. Prevalence of hypokalemia in older persons: results from the PolSenior national survey. Eur Geriatr Med. 2021;12(5):981-7.
223. Sur M, Mohiuddin SS. Potassium. StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2024, StatPearls Publishing LLC.; 2024.
224. Sevamontree C, Jintajirapan S, Phakdeekitcharoen P, Phakdeekitcharoen B. The Prevalence and Risk Factors of Hyperkalemia in the Outpatient Setting. Int J Nephrol. 2024;2024(1):5694131.
225. Ferreira JP, Butler J, Rossignol P, Pitt B, Anker SD, Kosiborod M, et al. Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(22):2836-50.
226. Hagengaard L, Søgaard P, Espersen M, Sessa M, Lund PE, Krogager ML, et al. Association between serum potassium levels and short-term mortality in patients with atrial fibrillation or flutter co-treated with diuretics and rate- or rhythm-controlling drugs. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):137-44.
227. Xi H, Yu RH, Wang N, Chen XZ, Zhang WC, Hong T. Serum potassium levels and mortality of patients with acute myocardial infarction: A systematic review and meta-analysis of cohort studies. Eur J Prev Cardiol. 2019;26(2):145-56.
228. Mount D. Causes of hypokalemia in adults: Uptodate; 2025 [Available from: https://www.uptodate.com/contents/causes-of-hypokalemia-in-adults?search=hypokalemia&source=search_result&selectedTitle=2%7E150&usage_type=default&display_rank=2].
229. Hunter RW, Bailey MA. Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant. 2019;34(Suppl 3):iii2-iii11.
230. Krishnaswami A, Steinman MA, Goyal P, Zullo AR, Anderson TS, Birtcher KK, et al. Deprescribing in Older Adults With Cardiovascular Disease. J Am Coll Cardiol. 2019;73(20):2584-95.
231. Wang GH-M, Morris EJ, Smith SM, Hallas J, Vouri SM. Continued potassium supplementation use following loop diuretic discontinuation in older adults: An evaluation of a prescribing cascade relic. J Am Geriatr Soc. 2023;71(2):505-15.
232. Henschke PJ, Spence JD, Cape RD. Diuretics and the institutional elderly: a case against routine potassium prescribing. J Am Geriatr Soc. 1981;29(4):145-50.
233. Peterson G, Dunbabin D. A guide to deprescribing: anticoagulants Tasmania: Primary Health Tasmania; 2022 [cited 2023 11 November]. Available from: https://www.primaryhealthtas.com.au/wp-content/uploads/2023/03/A-guide-to-deprescribing-anticoagulants.pdf.
234. Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. The Lancet. 2021;398(10294):64-77.
235. Ko D, Lin KJ, Bessette LG, Lee SB, Walkey AJ, Cheng S, et al. Trends in Use of Oral Anticoagulants in Older Adults With Newly Diagnosed Atrial Fibrillation, 2010-2020. JAMA Network Open. 2022;5(11):e2242964-e.
236. Norby FL, Lutsey PL, Shippee ND, Chen LY, Henning-Smith C, Alonso A, et al. Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation Treatment: Rural and Urban Trends in Medicare Beneficiaries. Am J Cardiovasc Drugs. 2022;22(2):207-17.
237. Mitchell A, Snowball J, Welsh TJ, Watson MC, McGrogan A. Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study. BMC Med. 2021;19(1):189.
238. Brieger D, Cullen L, Briffa T, Zaman S, Scott I, Papendick C, et al. National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Comprehensive Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025. Heart Lung Circ. 2025;34(4):309-97.
239. Rao SV, O’Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151(13):e771-e862.
240. Park DY, Hu J-R, Jamil Y, Kelsey MD, Jones WS, Frampton J, et al. Shorter Dual Antiplatelet Therapy for Older Adults After Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis. JAMA Network Open. 2024;7(3):e244000-e.
241. Watanabe H, Natsuaki M, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al. Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial. Eur Heart J. 2024;45(47):5042-54.
242. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2024;45(36):3314-414.
243. Brieger D, Amerena J, Attia J, Bajorek B, Chan KH, Connell C, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart, Lung and Circulation. 2018;27(10):1209-66.
244. Paciaroni M, Agnelli G, Ageno W, Caso V. Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. Thromb Haemost. 2016;116(3):410-6.
245. Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, et al. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open. 2019;9(3):e022478.
246. Pribish AM, Secemsky EA, Schmaier AA. Venous Thromboembolism for the Practicing Cardiologist. Cardiol Clin. 2021;39(4):551-66.
247. Chan KE, Giugliano RP, Patel MR, Abramson S, Jardine M, Zhao S, et al. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. J Am Coll Cardiol. 2016;67(24):2888-99.
248. Gažová A, Leddy JJ, Rexová M, Hlivák P, Hatala R, Kyselovič J. Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant). Medicine (Baltimore). 2019;98(31):e16560.
249. Chao TF, Chan YH, Chiang CE, Tuan TC, Liao JN, Chen TJ, et al. Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation. Clin Res Cardiol. 2022;111(1):23-33.
250. Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. Patient. 2017;10(1):17-37.
251. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2004;181(9):492-7.
252. Mearns S, Dunbabin D. A guide to deprescribing: antiplatelets Tasmania: Primary Health Tasmania; 2022 [cited 2023 11 November]. Available from: https://www.primaryhealthtas.com.au/wp-content/uploads/2023/03/A-guide-to-deprescribing-antiplatelets.pdf.
253. McNeil John J, Wolfe R, Woods Robyn L, Tonkin Andrew M, Donnan Geoffrey A, Nelson Mark R, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018;379(16):1509-18.
254. Zhou Z, Webb KL, Nelson MR, Woods RL, Ernst ME, Murray AM, et al. Short- and long-term impact of aspirin cessation in older adults: a target trial emulation. BMC Medicine. 2024;22(1):306.
255. Wolfe R, Wetmore JB, Woods RL, McNeil JJ, Gallagher H, Roderick P, et al. Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney Int. 2021;99(2):466-74.
256. Pallikadavath S, Ashton L, Brunskill NJ, Burton JO, Gray LJ, Major RW. Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;28(17):1953-60.
257. Limpijankit T, Jongjirasiri S, Unwanatham N, Rattanasiri S, Thakkinstian A, Laothamatas J. Causal Relationship of Coronary Artery Calcium on Myocardial Infarction and Preventive Effect of Antiplatelet Therapy. Front Cardiovasc Med. 2022;9:871267.
258. Miedema MD, Duprez DA, Misialek JR, Blaha MJ, Nasir K, Silverman MG, et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes. 2014;7(3):453-60.
259. Navarese EP, Andreotti F, Schulze V, Kołodziejczak M, Buffon A, Brouwer M, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015;350:h1618.
260. Rahman H, Khan SU, Nasir F, Hammad T, Meyer MA, Kaluski E. Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. Stroke. 2019;50(4):947-53.
261. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025-34.
262. Ziser K, Rahman S, Soro R, Falconer N, Harrop D. The role of triple antithrombotic therapy in patients with atrial fibrillation and coronary stent insertion. Australian Prescriber. 2025;48(1):18-22.
263. Matsumura-Nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, et al. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation. Circulation. 2019;139(5):604-16.
264. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019;381(12):1103-13.
265. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2024;45(36):3314-414.
266. Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2013;61(6):651-8.
267. Derogar M, Sandblom G, Lundell L, Orsini N, Bottai M, Lu Y, et al. Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. Clin Gastroenterol Hepatol. 2013;11(1):38-42.
268. Sambu N, Dent H, Englyst N, Warner TD, Leadbeater P, Roderick P, et al. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. Heart. 2011;97(20):1661-7.
269. Ramos VH, Hayes L, Simmons K, Trudeau B, Boka A. Pharmacist-Led Deprescribing of Aspirin in Older People in an Outpatient Setting. Sr Care Pharm. 2024;39(6):212-7.
270. Varghese CJ, Grunske M, Nagy MW. Implementation of a Pharmacist-Driven Aspirin Deprescribing Protocol Among Older Veterans in a Primary Care Setting. Sr Care Pharm. 2024;39(6):228-34.
271. Guralnik J, Ershler W, Artz A, Lazo-Langner A, Walston J, Pahor M, et al. Unexplained anemia of aging: Etiology, health consequences, and diagnostic criteria. J Am Geriatr Soc. 2022;70(3):891-9.
272. Turner J, Parsi M, Badireddy M. Anemia. StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2024, StatPearls Publishing LLC.; 2024.
273. Therapeutic Guidelines. Oral iron supplementation Melbourne: Therapeutic Guidelines Limited; 2022 [Available from: https://www.tg.org.au/].
274. Therapeutic Guidelines. Water-soluble vitamin deficiencies Melbourne: Therapeutic Guidelines Limited; 2023 [Available from: https://www.tg.org.au/].
275. Mouchaileh N. Vitamin B deficiency in older people: a practical approach to recognition and management. J Pharm Pract Res. 2023;53(6):350-8.
276. Dangour AD, Allen E, Clarke R, Elbourne D, Fletcher AE, Letley L, et al. Effects of vitamin B-12 supplementation on neurologic and cognitive function in older people: a randomized controlled trial. Am J Clin Nutr. 2015;102(3):639-47.
277. Ankar A, Kumar A. Vitamin B12 Deficiency. StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2025, StatPearls Publishing LLC.; 2025.
278. Świątczak M, Młodziński K, Sikorska K, Raczak A, Lipiński P, Daniłowicz-Szymanowicz L. Chronic Fatigue Syndrome in Patients with Deteriorated Iron Metabolism. Diagnostics (Basel). 2022;12(9).
279. Karamichalakis N, Letsas KP, Vlachos K, Georgopoulos S, Bakalakos A, Efremidis M, et al. Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vasc Health Risk Manag. 2015;11:555-62.
280. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156.
281. Yagnala N, Moreland-Head L, Zieminski JJ, Mara K, Macielak S. Assessment of Dofetilide or Sotalol Tolerability in the Elderly. J Cardiovasc Pharmacol Ther. 2024;29:10742484231224536.
282. Tatlisu MA, Ozcan KS, Gungor B, Zengin A, Karatas MB, Nurkalem Z. Inappropriate use of digoxin in patients presenting with digoxin toxicity. J Geriatr Cardiol. 2015;12(2):143-6.
283. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032.
284. Council of Australian Therapeutic Advisory Groups. MAIA Optimising guideline-directed medical therapy for HFrEF toolkit 2025 [Available from: https://catag.org.au/resource/maia-optimising-gdmt-hfref/].
285. Verma A, Kalman JM, Callans DJ. Treatment of Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction. Circulation. 2017;135(16):1547-63.
286. Verhaert DVM, Brunner-La Rocca HP, van Veldhuisen DJ, Vernooy K. The bidirectional interaction between atrial fibrillation and heart failure: consequences for the management of both diseases. Europace. 2021;23(23 Suppl 2):ii40-ii5.
287. Fauchier L, Laborie G, Clementy N, Babuty D. Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure? Card Fail Rev. 2016;2(1):35-9.
288. Gopinathannair R, Chen LY, Chung MK, Cornwell WK, Furie KL, Lakkireddy DR, et al. Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association. Circulation: Arrhythmia and Electrophysiology. 2021;14(7):e000078.
289. The Digitalis Investigation Group. The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. N Engl J Med. 1997;336(8):525-33.
290. Haynes K, Heitjan D, Kanetsky P, Hennessy S. Declining Public Health Burden of Digoxin Toxicity From 1991 to 2004. Clin Pharmacol Ther. 2008;84(1):90-4.
291. See I, Shehab N, Kegler SR, Laskar SR, Budnitz DS. Emergency Department Visits and Hospitalizations for Digoxin Toxicity. Circ Heart Fail. 2014;7(1):28-34.
292. Eisen A, Ruff CT, Braunwald E, Hamershock RA, Lewis BS, Hassager C, et al. Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF‐TIMI 48 Trial. J Am Heart Assoc. 2017;6(7):e006035.
293. Elliott W. Tapering and discontinuing antihypertensive medications 2025 [Available from: https://www.uptodate.com/contents/tapering-and-discontinuing-antihypertensive-medications#H2361771524].
294. Daly C, Edwards H. Withdrawal of digoxin in general practice in elderly patients. Ir Med J. 1983;76(1):19-20.
295. Fair JF. Supervised withdrawal of long-term digoxin therapy. Fam Pract. 1990;7(1):56-9.
296. Fonrose HA, Ahlbaum N, Bugatch E, Cohen M, Genovese C, Kelly J. The efficacy of digitalis withdrawal in an institutional aged population. J Am Geriatr Soc. 1974;22(5):208-11.
297. Macarthur C. Withdrawal of maintenance digoxin from institutionalized elderly. Postgrad Med J. 1990;66(781):940-2.
298. Sommers DK, Reitz CJ, Koch Z, Avenant JC. Digoxin withdrawal in patients with sinus rhythm. S Afr Med J. 1981;60(6):239-40.
299. Wilkins CE, Khurana MS. Digitalis withdrawal in elderly nursing home patients. J Am Geriatr Soc. 1985;33(12):850-1.
300. David MNV, Shetty M. Digoxin. StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2025, StatPearls Publishing LLC.; 2025.
301. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139-e228.
302. Lee PM, Gerriets V. Nitrates. StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2024, StatPearls Publishing LLC.; 2024.
303. Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119.
304. Australian Medicines Handbook [Online]. Adelaide: Australian Medicines Handbook Pty Ltd; 2025 [Available from: https://amhonline.amh.net.au/].
305. George J, Kitzis I, Zandorf D, Golovner M, Shapira I, Laniado S, et al. Safety of nitrate withdrawal in angina-free and hemodynamically stable patients with coronary artery disease. Chest. 2003;124(5):1652-7.
306. Jackson G, Martin E, McGing E, Cooper A. Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction. J Sex Med. 2005;2(4):513-6.
307. Benetos A, Petrovic M, Strandberg T. Hypertension Management in Older and Frail Older Patients. Circ Res. 2019;124(7):1045-60.
308. Wu CY, Hu HY, Chou YJ, Huang N, Chou YC, Li CP. High Blood Pressure and All-Cause and Cardiovascular Disease Mortalities in Community-Dwelling Older Adults. Medicine (Baltimore). 2015;94(47):e2160.
309. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. The Lancet. 2003;362(9395):1527-35.
310. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens. 2018;36(8):1637-47.
311. Parekh N, Page A, Ali K, Davies K, Rajkumar C. A practical approach to the pharmacological management of hypertension in older people. Ther Adv Drug Saf. 2017;8(4):117-32.
312. Morrissey Y, Bedford M, Irving J, Farmer CKT. Older people remain on blood pressure agents despite being hypotensive resulting in increased mortality and hospital admission. Age Ageing. 2016;45(6):783-8.
313. Morehead S, Dunbabin D. A guide to deprescribing: antihypertensives Tasmania: Primary Health Tasmania; 2022 [cited 2023 11 November]. Available from: https://www.primaryhealthtas.com.au/wp-content/uploads/2023/03/A-guide-to-deprescribing-antihypertensives.pdf.
314. Korzets A, Korzets Z, Zingerman B. Pseudohypertension in the Very Elderly: Important or Not? Isr Med Assoc J. 2023;25(1):68-9.
315. Messerli FH. Osler's maneuver, pseudohypertension, and true hypertension in the elderly. Am J Med. 1986;80(5):906-10.
316. Spence JD. Pseudohypertension. Hypertension. 2012;59(5):e49-e.
317. Bogaerts JMK, von Ballmoos LM, Achterberg WP, Gussekloo J, Streit S, van der Ploeg MA, et al. Do we AGREE on the targets of antihypertensive drug treatment in older adults: a systematic review of guidelines on primary prevention of cardiovascular diseases. Age Ageing. 2022;51(1).
318. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024;45(38):3912-4018.
319. National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults - 2016 Melbourne: National Heart Foundation of Australia; 2016 [Available from: https://www.heartfoundation.org.au/for-professionals/hypertension].
320. Jatos Study G. Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertens Res. 2008;31(12):2115-27.
321. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target Blood Pressure for Treatment of Isolated Systolic Hypertension in the Elderly. Hypertension. 2010;56(2):196-202.
322. Beckett Nigel S, Peters R, Fletcher Astrid E, Staessen Jan A, Liu L, Dumitrascu D, et al. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med.358(18):1887-98.
323. Masoli JAH, Delgado J, Pilling L, Strain D, Melzer D. Blood pressure in frail older adults: associations with cardiovascular outcomes and all-cause mortality. Age Ageing. 2020;49(5):807-13.
324. The SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med.373(22):2103-16.
325. Wang Z, Du X, Hua C, Li W, Zhang H, Liu X, et al. The Effect of Frailty on the Efficacy and Safety of Intensive Blood Pressure Control: A Post Hoc Analysis of the SPRINT Trial. Circulation. 2023;148(7):565-74.
326. Hu AH, Chang TI. SPRINT—A Kidney-Centric Narrative Review: Recent Advances in Hypertension. Hypertension. 2021;78(4):946-54.
327. Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019;321(6):553-61.
328. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385(14):1268-79.
329. Rockwood K, Theou O. Using the Clinical Frailty Scale in Allocating Scarce Health Care Resources. Can Geriatr J. 2020;23(3):210-5.
330. Australian Medicines Handbook [Online]. Adelaide: Australian Medicines Handbook Pty Ltd; 2025 [updated January 2025. Available from: https://amhonline.amh.net.au/.
331. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy. N Engl J Med. 2013;369(20):1892-903.
332. Misra S, Stevermer JJ. ACE inhibitors and ARBs: one or the other--not both--for high-risk patients. J Fam Pract. 2009;58(1):24-7.
333. Sica DA. Combination ACE inhibitor and angiotensin receptor blocker therapy - future considerations. J Clin Hypertens (Greenwich). 2007;9(1):78-86.
334. Lee JZ, Cha Y-M. Atrial fibrillation and heart failure: A contemporary review of current management approaches. Heart Rhythm O2. 2021;2(6, Part B):762-70.
335. Sheppard JP, Benetos A, McManus RJ. Antihypertensive Deprescribing in Older Adults: a Practical Guide. Curr Hypertens Rep. 2022;24(11):571-80.
336. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20.
337. Alsop K, Mac Mahon M. Withdrawing cardiovascular medications at a syncope clinic. Postgrad Med J. 2001;77(908):403-5.
338. Ekbom T, Lindholm LH, Odén A, Dahlöf B, Hansson L, Wester PO, et al. A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people. J Intern Med. 1994;235(6):581-8.
339. Espeland MA, Whelton PK, Kostis JB, Bahnson JL, Ettinger WH, Cutler JA, et al. Predictors and mediators of successful long-term withdrawal from antihypertensive medications. TONE Cooperative Research Group. Trial of Nonpharmacologic Interventions in the Elderly. Arch Fam Med. 1999;8(3):228-36.
340. Fotherby MD, Potter JF. Possibilities for antihypertensive drug therapy withdrawal in the elderly. J Hum Hypertens. 1994;8(11):857-63.
341. Gulla C, Flo E, Kjome RL, Husebo BS. Deprescribing antihypertensive treatment in nursing home patients and the effect on blood pressure. J Geriatr Cardiol. 2018;15(4):275-83.
342. Hajjar I, Hart M, Wan SH, Novak V. Safety and blood pressure trajectory of short-term withdrawal of antihypertensive medications in older adults: experience from a clinical trial sample. J Am Soc Hypertens. 2013;7(4):289-93.
343. Hassan D, Versmissen J, Hek K, van Dijk L, van den Bemt P. Feasibility of a protocol for deprescribing antihypertensive medication in older patients in Dutch general practices. BMC Prim Care. 2022;23(1):280.
344. Hearing SD, Wesnes KA, Bowman CE. Beta blockers and cognitive function in elderly hypertensive patients: withdrawal and consequences of ACE inhibitor substitution. Int J Geriatr Psychopharmacol. 1999;2(1):13‐7.
345. Jiménez-Candil J, Bermejo J, Yotti R, Cortina C, Moreno M, Cantalapiedra JL, et al. Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study. Heart. 2005;91(10):1311-8.
346. Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009;30(18):2186-92.
347. Juraschek SP, Cluett JL, Belanger MJ, Anderson TS, Ishak A, Sahni S, et al. Effects of Antihypertensive Deprescribing Strategies on Blood Pressure, Adverse Events, and Orthostatic Symptoms in Older Adults: Results From TONE. Am J Hypertens. 2022;35(4):337-46.
348. Kostis JB, Espeland MA, Appel L, Johnson KC, Pierce J, Wofford JL. Does withdrawal of antihypertensive medication increase the risk of cardiovascular events? Trial of Nonpharmacologic Interventions in the Elderly (TONE) Cooperative Research Group. Am J Cardiol. 1998;82(12):1501-8.
349. Lernfelt B, Landahl S, Svanborg A, Wikstrand J. Overtreatment of hypertension in the elderly? J Hypertens. 1990;8(5):483-90.
350. Moonen JEF, Foster-Dingley JC, de Ruijter W, van der Grond J, Bertens AS, van Buchem MA, et al. Effect of Discontinuation of Antihypertensive Treatment in Elderly People on Cognitive Functioning--the DANTE Study Leiden: A Randomized Clinical Trial. JAMA internal medicine. 2015;175(10):1622-30.
351. Nadal M, Wikström L, Allgulander S. Once hypertensive, always hypertensive? A three year follow-up after stopping medication. Scand J Prim Health Care. 1994;12(1):62-4.
352. Nelson MR, Reid CM, Krum H, Ryan P, Wing LM, McNeil JJ. Short-term predictors of maintenance of normotension after withdrawal of antihypertensive drugs in the second Australian National Blood Pressure Study (ANBP2). Am J Hypertens. 2003;16(1):39-45.
353. Sheppard JP, Burt J, Lown M, Temple E, Lowe R, Fraser R, et al. Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial. JAMA. 2020;323(20):2039-51.
354. Song W, Intrator O, Lee S, Boockvar K. Antihypertensive Drug Deintensification and Recurrent Falls in Long-Term Care. Health Serv Res. 2018;53(6):4066-86.
355. Hansen AG, Jensen H, Laugesen LP, Petersen A. Withdrawal of antihypertensive drugs in the elderly. Acta Med Scand Suppl. 1983;676:178-85.
356. Bogaerts JMK, Gussekloo J, de Jong-Schmit BEM, Le Cessie S, Mooijaart SP, van der Mast RC, et al. Effects of the discontinuation of antihypertensive treatment on neuropsychiatric symptoms and quality of life in nursing home residents with dementia (DANTON): a multicentre, open-label, blinded-outcome, randomised controlled trial. Age Ageing. 2024;53(7).
357. Silva IM, Moreira PM, Santos AM, Castro PR, Aguiar EC, Oliveira MG. Desprescribing antihypertensives in older people in primary care: subgroup analysis of the MINOR randomised clinical trial. Int J Clin Pharm. 2025;47(1):53-9.
358. Moonen JEF, Foster-Dingley JC, de Ruijter W, van der Grond J, de Craen AJM, van der Mast RC. Effect of discontinuation of antihypertensive medication on orthostatic hypotension in older persons with mild cognitive impairment: the DANTE Study Leiden. Age Ageing. 2016;45(2):249-55.
359. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management
London: Royal College of Physicians (UK); 2019 [Available from: https://www.nice.org.uk/guidance/ng136/chapter/Recommendations].
360. Sheppard JP, Temple E, Wang A, Smith A, Pollock S, Ford GA, et al. Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trial. Lancet Healthy Longev. 2024;5(8):e563-e73.
361. Nelson MR, Reid CM, Krum H, Muir T, Ryan P, McNeil JJ. Predictors of normotension on withdrawal of antihypertensive drugs in elderly patients: prospective study in second Australian national blood pressure study cohort. BMJ. 2002;325(7368):815.
362. Goyal A, Cusick AS, Bhutta BS. Peripheral Edema. StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2025, StatPearls Publishing LLC.; 2025.
363. Besharat S, Grol-Prokopczyk H, Gao S, Feng C, Akwaa F, Gewandter JS. Peripheral edema: A common and persistent health problem for older Americans. PLoS One. 2021;16(12):e0260742.
364. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-39.
365. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;27(12):1431-9.
366. Aubert CE, Rodondi N, Netzer S, Dalleur O, Spinewine A, Maanen CD-v, et al. Predictors of 1-year drug-related admissions in older multimorbid hospitalized adults. J Am Geriatr Soc. 2022;70(5):1510-6.
367. Dumbreck S, Flynn A, Nairn M, Wilson M, Treweek S, Mercer SW, et al. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ : British Medical Journal. 2015;350:h949.
368. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.
369. Health Quality & Safety Commission. HQSC Atlas of Healthcare Variation: People aged 65 and over who received the triple whammy Wellington. 2017 [Available from: https://www.hqsc.govt.nz/our-data/atlas-of-healthcare-variation/polypharmacy-in-people-aged-65-and-over/].
370. Magdy JS, McVeigh J, Indraratna P. Diuretics in the management of chronic heart failure: when and how. Aust Prescr. 2022;45(6):200-4.
371. Masella C, Viggiano D, Molfino I, Zacchia M, Capolongo G, Anastasio P, et al. Diuretic Resistance in Cardio-Nephrology: Role of Pharmacokinetics, Hypochloremia, and Kidney Remodeling. Kidney Blood Press Res. 2019;44(5):915-27.
372. Pratama AP, Hersunarti N, Soerarso R, Zahara R, Kurniawati Y, Hasanah DY, et al. Factors predicting diuretic resistance in patients with acute decompensated heart failure. Eur Heart J. 2022;43(Supplement_2):ehac544.874.
373. Rodríguez-Molinero A, Miñarro A, Narvaiza L, Gálvez-Barrón C, Gonzalo León N, Valldosera E, et al. Mortality in Elderly Patients Taking Furosemide: Prospective Cohorts Study. Int J Hypertens. 2022;2022:4708259.
374. Fosnight S, Soric MM, Smearman J, Graves E, Vazquez M, Herrington Z, et al. Investigation Into Potentially Inappropriate Prescribing Patterns of Loop Diuretics in a Nationally Representative Outpatient Population. Am J Ther. 2024;31(4).
375. Damoiseaux-Volman BA, Medlock S, Raven K, Sent D, Romijn JA, van der Velde N, et al. Potentially inappropriate prescribing in older hospitalized Dutch patients according to the STOPP/START criteria v2: a longitudinal study. Eur J Clin Pharmacol. 2021;77(5):777-85.
376. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17.
377. Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. The Lancet. 2024;404(10458):1119-31.
378. Kurgansky KE, Parker R, Djousse L, Gagnon DR, Joseph J. Spironolactone Reduces the Risk of Death in Veterans With Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2024;13(14):e032231.
379. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-29.
380. Arumugham VB, Shahin MH. Therapeutic Uses of Diuretic Agents. StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2025, StatPearls Publishing LLC.; 2025.
381. Burr ML, King S, Davies HE, Pathy MS. The effects of discontinuing long-term diuretic therapy in the elderly. Age Ageing. 1977;6(1):38-45.
382. de Jonge JW, Knottnerus JA, van Zutphen WM, de Bruijne GA, Struijker Boudier HA. Short term effect of withdrawal of diuretic drugs prescribed for ankle oedema. BMJ. 1994;308(6927):511-3.
383. Myers MG, Weingert ME, Fisher RH, Gryfe CI, Shulman HS. Unnecessary diuretic therapy in the elderly. Age Ageing. 1982;11(4):213-21.
384. Straand J, Fugelli P, Laake K. Withdrawing long-term diuretic treatment among elderly patients in general practice. Fam Pract. 1993;10(1):38-42.
385. van Kraaij DJ, Jansen RW, Bouwels LH, Gribnau FW, Hoefnagels WH. Furosemide withdrawal in elderly heart failure patients with preserved left ventricular systolic function. Am J Cardiol. 2000;85(12):1461-6.
386. Walma EP, Hoes AW, Prins A, Boukes FS, van der Does E. Withdrawing long-term diuretic therapy in the elderly: a study in general practice in The Netherlands. Fam Med. 1993;25(10):661-4.
387. Walma EP, Hoes AW, van Dooren C, Prins A, van der Does E. Withdrawal of long-term diuretic medication in elderly patients: a double blind randomised trial. BMJ. 1997;315(7106):464-8.
388. Ong J, Newman D, Sharma N, Ooi JL. The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review. Aust J Gen Pract. 2015;44:367-70.
389. Thompson W, Pottegård A, Nielsen JB, Haastrup P, Jarbøl DE. How Common is Statin Use in the Oldest Old? Drugs Aging. 2018;35(8):679-86.
390. Zoungas S, Curtis A, Spark S, Wolfe R, McNeil JJ, Beilin L, et al. Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). BMJ Open. 2023;13(4):e069915.
391. Joseph J, Pajewski NM, Dolor RJ, Sellers MA, Perdue LH, Peeples SR, et al. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. J Am Geriatr Soc. 2023;71(6):1701-13.
392. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-30.
393. Ramos R, Comas-Cufí M, Martí-Lluch R, Balló E, Ponjoan A, Alves-Cabratosa L, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. BMJ. 2018;362:k3359.
394. Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, et al. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. JAMA Internal Medicine. 2017;177(7):955-65.
395. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152(8):488-96, w174.
396. Savarese G, Gotto AM, Jr., Paolillo S, D'Amore C, Losco T, Musella F, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62(22):2090-9.
397. Teng M, Lin L, Zhao YJ, Khoo AL, Davis BR, Yong QW, et al. Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-Analysis. Drugs Aging. 2015;32(8):649-61.
398. Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637-43.
399. Heart Foundation. 2023 Guideline for assessing and managing CVD risk and Australian CVD risk calculator 2023 [Available from: https://www.heartfoundation.org.au/for-professionals/guideline-for-managing-cvd].
400. Chua A, Blankstein R, Ko B. Coronary artery calcium in primary prevention. Aust J Gen Pract. 2020;49:464-9.
401. Liu W, Zhang Y, Yu CM, Ji QW, Cai M, Zhao YX, et al. Current understanding of coronary artery calcification. J Geriatr Cardiol. 2015;12(6):668-75.
402. Armitage J, Baigent C, Barnes E, Betteridge DJ, Blackwell L, Blazing M, et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet. 2019;393(10170):407-15.
403. Bétrisey S, Haller ML, Efthimiou O, Speierer A, Del Giovane C, Moutzouri E, et al. Lipid‐Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2024;13(4):e030714.
404. Cerit L, Duygu H, Gulsen K, Gunsel A. Effect of statins on coronary blood flow after percutaneous coronary intervention in patients with stable coronary artery disease. Neth Heart J. 2017;25(4):258-63.
405. Mood GR, Bavry AA, Roukoz H, Bhatt DL. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol. 2007;100(6):919-23.
406. Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiology. 2017;2(1):47-54.
407. Orkaby AR, Driver JA, Ho YL, Lu B, Costa L, Honerlaw J, et al. Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older. JAMA. 2020;324(1):68-78.
408. Gupta A, Burgess R, Drozd M, Gierula J, Witte K, Straw S. The Surprise Question and clinician-predicted prognosis: systematic review and meta-analysis. BMJ Support Palliat Care. 2024;15(1):12-35.
409. Chung CM, Lin MS, Liu CH, Lee TH, Chang ST, Yang TY, et al. Discontinuing or continuing statin following intracerebral hemorrhage from the view of a national cohort study. Atherosclerosis. 2018;278:15-22.
410. Korsholm MB, Pødenphanth TW, Strømgaard SK, Petersen LW, Alexandersen C, Hoffmann SS, et al. Are statins making older persons weaker? A discontinuation study of muscular side effects. Geroscience. 2024;46(1):853-65.
411. Kutner JS, Blatchford PJ, Taylor DH, Jr., Ritchie CS, Bull JH, Fairclough DL, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175(5):691-700.
412. Stacey SK, McEleney M. Topical Corticosteroids: Choice and Application. Am Fam Physician. 2021;103(6):337-43.
413. Rathi SK, D'Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol. 2012;57(4):251-9.
414. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-32.
415. Therapeutic Guidelines. Principles of dermatitis management Melbourne: Therapeutic Guidelines Limited; 2022 [Available from: https://www.tg.org.au/].
416. Sheary B. Topical corticosteroid addiction and withdrawal – An overview for GPs. Aust J Gen Pract. 2016;45:386-8.
417. Mohta A, Sathe NC. Topical Steroid Withdrawal (Red Skin Syndrome). StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2025, StatPearls Publishing LLC.; 2025.
418. Australasian Menopause Society. Management Area 2024 [Available from: https://www.menopause.org.au/index.php?option=com_content&view=article&id=487:management-area&catid=104&Itemid=245].
419. Bachmann G, Pinkerton JV. Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment: Uptodate; 2025 [Available from: https://www.uptodate.com/contents/genitourinary-syndrome-of-menopause-vulvovaginal-atrophy-treatment#H2764255704].
420. Australasian Menopause Society. Genitourinary Syndrome of Menopause 2024 [Available from: https://www.menopause.org.au/hp/information-sheets/genitourinary-syndrome-of-menopause#:~:text=Genitourinary%20Syndrome%20of%20Menopause%20is,in%20women%20aged%2040%2D45.].
421. Therapeutic Guidelines. Systemic menopausal hormone therapy (MHT) Melbourne: Therapeutic Guidelines Limited; 2020 [Available from: https://www.tg.org.au/].
422. Bachmann G, Pinkerton JV. Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment.: UptoDate; 2024 [Available from: https://www.uptodate.com/contents/genitourinary-syndrome-of-menopause-vulvovaginal-atrophy-treatment?search=Low-dose%20vaginal%20estrogen%20can%20generally%20be%20used%20long-term%2C%20given%20the%20low%20risk%20of%20adverse%20effects.%20However%2C%20there%20is%20a%20lack%20of%20long-term%20trials%20beyond%20one%20year%20&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1].
423. Gallagher JC, Rapuri PB, Haynatzki G, Detter JR. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab. 2002;87(11):4914-23.
424. Lindh-Astrand L, Bixo M, Hirschberg AL, Sundström-Poromaa I, Hammar M. A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms. Menopause. 2010;17(1):72-9.
425. Martin K, Barbieri RL. Treatment of menopausal symptoms with hormone therapy: UptoDate; 2025 [Available from: https://www.uptodate.com/contents/treatment-of-menopausal-symptoms-with-hormone-therapy?search=menopause%20hormonal%20reducing%20the%20dose%20or%20dosing%20frequency.%20For%20example%3A%20%E2%80%A2For%20oral%20formulations%2C%20reduce%20one%20dose%20per%20week%20every%20two%20to%20four%20weeks%3B%20or%20%E2%80%A2For%20transdermal%20formulations%2C%20gradually%20lower%20the%20patch%20strength%20over%20a%20period%20of%20three%20to%20six%20months%2C%20depending%20on%20the%20available%20dosage%20forms%3B%20or%20%E2%80%A2For%20gel%2C%20cream%20or%20pessary%20formulations%2C%20reduce%20the%20dosing%20frequency%20every%20two%20to%20four%20weeks.&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1].
426. Hutchinson A, Nesbitt A, Joshi A, Clubb A, Perera M. Overactive bladder syndrome: Management and treatment options. Aust J Gen Pract. 2020;49:593-8.
427. Chang HJ, Lynm C, Glass RM. Urinary Incontinence in Older Women. JAMA. 2010;303(21):2208-.
428. Ha M, Furman A, Al Rihani SB, Michaud V, Turgeon J, Bankes DL. Pharmacist-driven interventions to de-escalate urinary antimuscarinics in the Programs of All-Inclusive Care for the Elderly. J Am Geriatr Soc. 2022;70(11):3230-8.
429. Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023(5).
430. Kalisch LM, Caughey GE, Roughead EE, Gilbert AL. The prescribing cascade. Australian prescriber. 2011;34(6):162-6.
431. Gill SS, Mamdani M, Naglie G, Streiner DL, Bronskill SE, Kopp A, et al. A Prescribing Cascade Involving Cholinesterase Inhibitors and Anticholinergic Drugs. Arch Intern Med. 2005;165(7):808-13.
432. McVary K, Saini R. Lower urinary tract symptoms in males: UptoDate; 2025 [Available from: https://www.uptodate.com/contents/lower-urinary-tract-symptoms-in-males?search=many%20commonly%20used%20drugs%20can%20also%20exacerbate%20low%20urinary%20tract%20symptoms%20%28LUTS&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1].
433. Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(2):209-20.
434. Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781-7.
435. Welk B, McArthur E, Fraser L-A, Hayward J, Dixon S, Hwang YJ, et al. The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study. BMJ. 2015;351:h5398.
436. Al-Kharashi A, Azimzadeh AA, Leung J, Radomski S, Radomski L, Lam WC. Anterior segment optical coherence tomography changes with introduction and discontinuation of tamsulosin. Saudi J Ophthalmol. 2016;30(3):150-6.
437. Bahri S, Malcomson B, Ball K, Bhrambhatt D, Beatty J. 714 An Evaluation of The Discontinuation of Tamsulosin and Finasteride Post Transurethral Resection of The Prostate (TURP) At UHL. Br J Surg. 2021;108(Supplement_6).
438. ÖZtÜRk C, Cevher S, Duran M, Ekici M. The Effect of Tamsulosin on Iris Morphology, Ciliary Muscle Thickness, and Pupil Diameter. Am J Ophthalmol. 2025;271:389-95.
439. Pärssinen O, Leppänen E, Keski-Rahkonen P, Mauriala T, Dugué B, Lehtonen M. Influence of tamsulosin on the iris and its implications for cataract surgery. Invest Ophthalmol Vis Sci. 2006;47(9):3766-71.
440. Bell CM, Hatch WV, Fischer HD, Cernat G, Paterson JM, Gruneir A, et al. Association Between Tamsulosin and Serious Ophthalmic Adverse Events in Older Men Following Cataract Surgery. JAMA. 2009;301(19):1991-6.
441. Lin VC, Liao CH, Kuo HC. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study. Urology. 2014;83(2):416-21.
442. Parian A, Ha CY. Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(6):1392-400.
443. Scottish Government Polypharmacy Model of Care Group. Polypharmacy Guidance, Realistic Prescribing 3rd ed. Scotland: Scottish Goverment; 2018.
444. Therapeutic Guidelines. Polymyalgia rheumatica Melbourne: Therapeutic Guidelines Limited; 2024 [Available from: https://www.tg.org.au/].
445. Borresen SW, Klose M, Glintborg D, Watt T, Andersen MS, Feldt-Rasmussen U. Approach to the Patient With Glucocorticoid-induced Adrenal Insufficiency. J Clin Endocrinol Metab. 2022;107(7):2065-76.
446. Beuschlein F, Else T, Bancos I, Hahner S, Hamidi O, van Hulsteijn L, et al. European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency. J Clin Endocrinol Metab. 2024;109(7):1657-83.
447. Esselinckx W, Doherty SM, Dixon AS. Polymyalgia rheumatica. Abrupt and gradual withdrawal of prednisolone treatment, clinical and laboratory observations. Ann Rheum Dis. 1977;36(3):219-24.
448. Hirano K, Tada M, Isayama H, Sasahira N, Umefune G, Akiyama D, et al. Outcome of Long-term Maintenance Steroid Therapy Cessation in Patients With Autoimmune Pancreatitis: A Prospective Study. J Clin Gastroenterol. 2016;50(4):331-7.
449. Hirata S, Kohno H, Watanabe H, Tokunaga T, Yoshida Y, Sugimoto T, et al. Tapering and discontinuation of oral glucocorticoids without deterioration of disease status in patients with rheumatoid arthritis under a stable treatment. Mod Rheumatol. 2021;31(4):803-8.
450. Rice KL, Rubins JB, Lebahn F, Parenti CM, Duane PG, Kuskowski M, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am J Respir Crit Care Med. 2000;162(1):174-8.
451. Almayali AAH, Boers M, Hartman L, Opris D, Bos R, Kok MR, et al. Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial. Ann Rheum Dis. 2023;82(10):1307-14.
452. Goto Y, Nagafuchi H, Kaga Y, Kawahata K. Association between glucocorticoid discontinuation and incidence of infection in older adults with rheumatoid arthritis: A retrospective cohort study. Int J Rheum Dis. 2023;26(10):1987-95.
453. Theiler-Schwetz V, Prete A. Glucocorticoid withdrawal syndrome: what to expect and how to manage. Current Opinion in Endocrinology, Diabetes and Obesity. 2023;30(3).
454. Pelewicz K, Miśkiewicz P. Glucocorticoid Withdrawal-An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice. Diagnostics (Basel). 2021;11(4).
455. He J, Lai Y, Yang J, Yao Y, Li Y, Teng W, et al. The Relationship Between Thyroid Function and Metabolic Syndrome and Its Components: A Cross-Sectional Study in a Chinese Population. Front Endocrinol (Lausanne). 2021;12:661160.
456. Leng O, Razvi S. Hypothyroidism in the older population. Thyroid Res. 2019;12:2.
457. Therapeutic Guidelines. Thyroid disorders Melbourne: Therapeutic Guidelines Limited; 2019 [Available from: https://www.tg.org.au/].
458. Ravensberg AJ, Poortvliet RKE, Du Puy RS, Dekkers OM, Mooijaart SP, Gussekloo J. Effects of discontinuation of levothyroxine treatment in older adults: protocol for a self-controlled trial. BMJ Open. 2023;13(4):e070741.
459. The Royal Australian College of General Practitioners. Management of subclinical hypothyroidism. East Melbourne, Vic: RACGP; 2022.
460. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526-34.
461. Cooper R, Pinkney J, Ayling RM. Appropriateness of prescribing thyroxine in primary care. Ann Clin Biochem. 2015;52(Pt 4):497-501.
462. Allport J, McCahon D, Hobbs FD, Roberts LM. Why are GPs treating subclinical hypothyroidism? Case note review and GP survey. Prim Health Care Res Dev. 2013;14(2):175-84.
463. Stuber MJ, Moutzouri E, Feller M, Del Giovane C, Bauer DC, Blum MR, et al. Effect of Thyroid Hormone Therapy on Fatigability in Older Adults With Subclinical Hypothyroidism: A Nested Study Within a Randomized Placebo-Controlled Trial. J Gerontol A Biol Sci Med Sci. 2020;75(9):e89-e94.
464. Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RGJ, Mooijaart SP, et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med. 2017;376(26):2534-44.
465. Andersen MN, Olsen AS, Madsen JC, Kristensen SL, Faber J, Torp-Pedersen C, et al. Long-Term Outcome in Levothyroxine Treated Patients With Subclinical Hypothyroidism and Concomitant Heart Disease. J Clin Endocrinol Metab. 2016;101(11):4170-7.
466. Evron JM, Hummel SL, Reyes-Gastelum D, Haymart MR, Banerjee M, Papaleontiou M. Association of Thyroid Hormone Treatment Intensity With Cardiovascular Mortality Among US Veterans. JAMA Netw Open. 2022;5(5):e2211863.
467. De Weerd - Slot M, Schipper MH, Siegert CEH, Marmorale A, Becker ML, Karapinar-Carkit F. 4CPS-102 Amiodarone and lithium-induced thyroid dysfunction: who initiates the prescribing cascade? Eur J Hosp Pharm. 2024;31(Suppl 1):A100.
468. Hughes K, Eastman C. Thyroid disease: Long-term management of hyperthyroidism and hypothyroidism. Aust J Gen Pract. 2021;50:36-42.
469. Coll PP, Abourizk NN. Successful withdrawal of thyroid hormone therapy in nursing home patients. J Am Board Fam Pract. 2000;13(6):403-7.
470. International Osteoporosis Foundation. Anabolics 2025 [Available from: https://www.osteoporosis.foundation/health-professionals/treatment/anabolics].
471. Díez-Pérez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodríguez M. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis. Bone. 2019;120:1-8.
472. Sheng OC, Wu W-T, Peng C-H, Yao T-K, Chen I-H, Wang J-H, et al. Therapeutic advantage of teriparatide in very elderly patients with proximal femoral fractures: a functional and BMD analysis. BMC Musculoskelet Disord. 2024;25(1):288.
473. Rosen CJ. Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis: UptoDate; 2025 [Available from: https://www.uptodate.com/contents/parathyroid-hormone-parathyroid-hormone-related-protein-analog-therapy-for-osteoporosis?search=Teriparatide%20&source=search_result&selectedTitle=2%7E150&usage_type=default&display_rank=1].
474. Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates. JBMR Plus. 2022;6(9):e10665.
475. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353(6):555-65.
476. Minne H, Audran M, Simões ME, Obermayer-Pietsch B, Sigurðsson G, Marín F, et al. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin. 2008;24(11):3117-28.
477. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386(9999):1147-55.
478. Nandy S, Parsons S, Cryer C, Underwood M, Rashbrook E, Carter Y, et al. Development and preliminary examination of the predictive validity of the Falls Risk Assessment Tool (FRAT) for use in primary care. J Public Health (Oxf). 2004;26(2):138-43.
479. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents. J Clin Endocrinol Metab. 2002;87(4):1586-92.
480. The Royal Australian College of General Practitioners (RACGP) and Healthy Bones Australia. Osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age: RACGP; 2024 [Available from: https://healthybonesaustralia.org.au/wp-content/uploads/2024/03/hba-racgp-guidelines-2024.pdf].
481. Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab. 2009;94(8):2915-21.
482. Enthoven WTM, Roelofs P, Deyo RA, van Tulder MW, Koes BW. Non‐steroidal anti‐inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016(2).
483. Pattanittum P, Turner T, Green S, Buchbinder R. Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults. Cochrane Database Syst Rev. 2013(5).
484. Rasmussen‐Barr E, Held U, Grooten WJA, Roelofs P, Koes BW, van Tulder MW, et al. Non‐steroidal anti‐inflammatory drugs for sciatica. Cochrane Database Syst Rev. 2016(10).
485. Roelofs P, Deyo RA, Koes BW, Scholten R, van Tulder MW. Non‐steroidal anti‐inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008(1).
486. Salis Z, Sainsbury A. Association of long-term use of non-steroidal anti-inflammatory drugs with knee osteoarthritis: a prospective multi-cohort study over 4-to-5 years. Sci Rep. 2024;14(1):6593.
487. Mearns S, Dunbabin D. A guide to deprescribing: non-steroidal anti-inflammatory drugs Tasmania: Primary Health Tasmania; 2022 [cited 2023 11 November]. Available from: https://www.primaryhealthtas.com.au/wp-content/uploads/2023/03/A-guide-to-deprescribing-non-steroidal-anti-inflammatory-drugs.pdf.
488. Therapeutic Guidelines. Osteoarthritis Melbourne: Therapeutic Guidelines Limited; 2024 [Available from: https://www.tg.org.au/].
489. Rannou F, Pelletier JP, Martel-Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(4 Suppl):S18-21.
490. Guedes V, Castro JP, Brito I. Topical capsaicin for pain in osteoarthritis: A literature review. Reumatol Clin (Engl Ed). 2018;14(1):40-5.
491. Therapeutic Guidelines. Pain and Analgesia Melbourne: Therapeutic Guidelines Limited; 2020 [Available from: https://www.tg.org.au/].
492. O'Mahony L, Duffy E, Mc Ginnity M, Balmer F, Duffy I. NSAIDs and Renal Impairment: Deprescribing Chronic NSAID use in General Practice. Ir Med J. 2021;114(8):431.
493. Rashid R, Chang C, Niu F, Deguzman L, Draves M, Awsare S, et al. Evaluation of a Pharmacist-Managed Nonsteroidal Anti-Inflammatory Drugs Deprescribing Program in an Integrated Health Care System. J Manag Care Spec Pharm. 2020;26(7):918-24.
494. Therapeutic Guidelines. Gout Melbourne: Therapeutic Guidelines Limited; 2021 [Available from: https://www.tg.org.au/].
495. Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, et al. Gout. Nature Reviews Disease Primers. 2019;5(1):69.
496. Australian Institute of Health and Welfare. Chronic musculoskeletal conditions: gout Canberra: AIHW; 2023 [Available from: https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout].
497. Major TJ, Topless RK, Dalbeth N, Merriman TR. Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts. BMJ. 2018;363:k3951.
498. Syed AAS, Fahira A, Yang Q, Chen J, Li Z, Chen H, et al. The Relationship between Alcohol Consumption and Gout: A Mendelian Randomization Study. Genes (Basel). 2022;13(4).
499. Casas R, Ribó-Coll M, Ros E, Fitó M, Lamuela-Raventos RM, Salas-Salvadó J, et al. Change to a healthy diet in people over 70 years old: the PREDIMED experience. Eur J Nutr. 2022;61(3):1429-44.
500. Saito Y, Tanaka A, Node K, Kobayashi Y. Uric acid and cardiovascular disease: A clinical review. J Cardiol. 2021;78(1):51-7.
501. Ken C, Billy W, Suneela M, Matire H, Corina G, Nicola D, et al. Association between gout and cardiovascular outcomes in adults with no history of cardiovascular disease: large data linkage study in New Zealand. BMJ Medicine. 2022;1(1):e000081.
502. Chen Q, Wang Z, Zhou J, Chen Z, Li Y, Li S, et al. Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2020;15(11):1576-86.
503. Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum. 2006;55(5):786-90.
504. Morehead S, Dunbabin D. A guide to deprescribing: allopurinol Tasmania: Primary Health Tasmania; 2022 [cited 2023 11 November]. Available from: https://www.primaryhealthtas.com.au/wp-content/uploads/2023/03/A-guide-to-deprescribing-allopurinol.pdf.
505. Beslon V, Moreau P, Maruani A, Maisonneuve H, Giraudeau B, Fournier JP. Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review. J Gen Intern Med. 2018;33(3):358-66.
506. Fenando A, Rednam M, Gujarathi R, Widrich J. Gout. StatPearls. Treasure Island (FL): StatPearls PublishingCopyright © 2025, StatPearls Publishing LLC.; 2025.
507. Clarson LE, Chandratre P, Hider SL, Belcher J, Heneghan C, Roddy E, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(3):335-43.
508. International Osteoporosis Foundation. Calcium No date [Available from: https://www.osteoporosis.foundation/educational-hub/topic/calcium-calculator].
509. The Royal Australian College of General Practitioners (RACGP) and Healthy Bones Australia. Osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age 2024 [Available from: https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/osteoporosis/executive-summary].
510. Oudshoorn C, Hartholt KA, van Leeuwen JP, Colin EM, van der Velde N, van der Cammen TJ. Better knowledge on vitamin D and calcium in older people is associated with a higher serum vitamin D level and a higher daily dietary calcium intake. Health Educ J. 2012;71(4):474-82.
511. Neale RE, Beedle V, Ebeling PR, Elliott T, Francis D, Girgis CM, et al. Balancing the risks and benefits of sun exposure: A revised position statement for Australian adults. Aust N Z J Public Health. 2024;48(1):100117.
512. Winzenberg T, van der Mei I, Mason RS, Nowson C, Jones G. Vitamin D. Aust J Gen Pract. 2012;41:92-9.
513. Giustina A, Bouillon R, Dawson-Hughes B, Ebeling PR, Lazaretti-Castro M, Lips P, et al. Vitamin D in the older population: a consensus statement. Endocrine. 2023;79(1):31-44.
514. Nowson CA, McGrath JJ, Ebeling PR, Haikerwal A, Daly RM, Sanders KM, et al. Vitamin D and health in adults in Australia and New Zealand: a position statement. Med J Aust. 2012;196(11):686-7.
515. Seamans KM, Cashman KD. Existing and potentially novel functional markers of vitamin D status: a systematic review234. Am J Clin Nutr. 2009;89(6):1997S-2008S.
516. Lucas R, Neale R. What is the optimal level of vitamin D? Aust J Gen Pract. 2014;43:119-22.
517. Jukic AMZ, Hoofnagle AN, Lutsey PL. Measurement of Vitamin D for Epidemiologic and Clinical Research: Shining Light on a Complex Decision. Am J Epidemiol. 2018;187(4):879-90.
518. Healthy Bones Australia. Vitamin D and Bone Health: Healthy Bones Australia; 2024 [Available from: https://healthybonesaustralia.org.au/wp-content/uploads/2024/10/hba-fact-sheet-vitamin-d-v2-15-08-24.pdf].
519. Bilinski K, Boyages S. Evidence of overtesting for vitamin D in Australia: an analysis of 4.5 years of Medicare Benefits Schedule (MBS) data. BMJ Open. 2013;3(6).
520. Avenell A, Mak JC, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev. 2014;2014(4):Cd000227.
521. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040.
522. Lewis JR, Radavelli-Bagatini S, Rejnmark L, Chen JS, Simpson JM, Lappe JM, et al. The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. J Bone Miner Res. 2015;30(1):165-75.
523. Prince RL, Devine A, Dhaliwal SS, Dick IM. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med. 2006;166(8):869-75.
524. Reid IR, Mason B, Horne A, Ames R, Reid HE, Bava U, et al. Randomized controlled trial of calcium in healthy older women. Am J Med. 2006;119(9):777-85.
525. Flicker L, MacInnis RJ, Stein MS, Scherer SC, Mead KE, Nowson CA, et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. J Am Geriatr Soc. 2005;53(11):1881-8.
526. The Royal Australian College of General Practitioners. General bone health maintenance and fracture prevention: Calcium, protein and Vitamin D East Melbourne, Vic: RACGP; 2017 [Available from: https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/osteoporosis/general-bone-health-maintenance/calcium-protein-and-vitamin-d].
527. Burton JO, Goldsmith DJ, Ruddock N, Shroff R, Wan M. Renal association commentary on the KDIGO (2017) clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. BMC Nephrol. 2018;19(1):240.
528. Sridharan K. Chronic kidney disease mineral and bone disorder: A guide for general practice. Aust J Gen Pract. 2023;52:52-7.
529. Anagnostis P, Bosdou JK, Kenanidis E, Potoupnis M, Tsiridis E, Goulis DG. Vitamin D supplementation and fracture risk: Evidence for a U-shaped effect. Maturitas. 2020;141:63-70.
530. Wanigatunga AA, Sternberg AL, Blackford AL, Cai Y, Mitchell CM, Roth DL, et al. The effects of vitamin D supplementation on types of falls. J Am Geriatr Soc. 2021;69(10):2851-64.
531. Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes Endocrinol. 2018;6(11):847-58.
532. Cameron ID, Gillespie LD, Robertson MC, Murray GR, Hill KD, Cumming RG, et al. Interventions for preventing falls in older people in care facilities and hospitals. Cochrane Database Syst Rev. 2012;12:Cd005465.
533. Chou SH, Cook NR, Kotler G, Kim E, Copeland T, Lee IM, et al. Effects of Supplemental Vitamin D3, Omega-3 Fatty Acids on Physical Performance Measures in the VITamin D and OmegA-3 TriaL. J Clin Endocrinol Metab. 2024;110(1):e44-e53.
534. Bischoff-Ferrari HA, Vellas B, Rizzoli R, Kressig RW, da Silva JAP, Blauth M, et al. Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial. JAMA. 2020;324(18):1855-68.
535. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. Am J Clin Nutr. 2000;72(3):745-50.
536. Radford LT, Bolland MJ, Mason B, Horne A, Gamble GD, Grey A, et al. The Auckland calcium study: 5-year post-trial follow-up. Osteoporos Int. 2014;25(1):297-304.
537. Rosen H. Calcium and vitamin D supplementation in osteoporosis: UptoDate; 2024 [Available from: https://www.uptodate.com/contents/calcium-and-vitamin-d-supplementation-in-osteoporosis?search=1300%20mg%20of%20calcium%20and%20800%20units%20of%20vitamin%20D&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1].
538. Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, et al. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. J Clin Oncol. 2017;35(35):3978-86.
539. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74(11):1385-93.
540. Troncoso-Mariño A, Lestón Vázquez M, Gallardo Borge S, Del Val Garcia JL, Amado Guirado E, Violán C. Fracture risk after deprescription of bisphosphonates: Application of real-world data in primary care. Aten Primaria. 2023;55(7):102651.
541. Jepsen DB, Bergen ES, Pan J, van Poelgeest E, Osman A, Burghle A, et al. Recommendations on deprescribing of bisphosphonates in osteoporosis guidelines: a systematic review. Eur Geriatr Med. 2023;14(4):747-60.
542. Jak X. A guide to deprescribing: bisphosphonates Tasmania: Primary Health Tasmania; 2022 [cited 2024 23 August]. Available from: https://www.primaryhealthtas.com.au/wp-content/uploads/2023/03/A-guide-to-deprescribing-bisphosphonates.pdf.
543. Deardorff WJ, Cenzer I, Nguyen B, Lee SJ. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine. 2022;182(1):33-41.
544. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23.
545. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267-94.
546. LeBlanc ES, Hillier TA, Pedula KL, Rizzo JH, Cawthon PM, Fink HA, et al. Hip Fracture and Increased Short-term but Not Long-term Mortality in Healthy Older Women. Arch Intern Med. 2011;171(20):1831-7.
547. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-38.
548. Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010;25(5):976-82.
549. Jak X, Dunbabin D. A guide to deprescribing: bisphophonates Tasmania: Primary Health Tasmania; 2022 [cited 2023 11 November]. Available from: https://www.primaryhealthtas.com.au/wp-content/uploads/2023/03/A-guide-to-deprescribing-bisphosphonates.pdf.
550. Cowan A, Jeyakumar N, McArthur E, Fleet JL, Kanagalingam T, Karp I, et al. Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population‐Based Cohort Study. J Bone Miner Res. 2023;38(5):650-8.
551. Yong C. Denosumab-related hypocalcaemia in chronic kidney disease. Aust J Gen Pract. 2018;47:538-9.
552. Okuno F, Ito-Masui A, Hane A, Maeyama K, Ikejiri K, Ishikura K, et al. Severe hypocalcemia after denosumab treatment leading to refractory ventricular tachycardia and veno-arterial extracorporeal membrane oxygenation support: a case report. Int J Emerg Med. 2023;16(1):52.
553. United States Food and Drug Administration (FDA). Prolia (denosumab): Drug Safety Communication - FDA Adds Boxed Warning for Increased Risk of Severe Hypocalcemia in Patients with Advanced Chronic Kidney Disease: Patients on Dialysis or with Mineral and Bone Disorder at Highest Risk United States: FDA; 2024 [Available from: https://www.fda.gov/safety/medical-product-safety-information/prolia-denosumab-drug-safety-communication-fda-adds-boxed-warning-increased-risk-severe-hypocalcemia#:~:text=In%20patients%20with%20advanced%20CKD,warning%2C%20communicating%20this%20increased%20risk].
554. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972-80.
555. Lyu H, Yoshida K, Zhao SS, Wei J, Zeng C, Tedeschi SK, et al. Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis : A Population-Based Cohort Study. Ann Intern Med. 2020;173(7):516-26.
556. Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas. 2017;101:23-30.
557. Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwiński E, et al. Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. J Bone Miner Res. 2019;34(6):1033-40.
558. Lee J, Lee YJ, Ha J. Denosumab in Osteoporosis: Predicting Long-Term Efficacy beyond 10 Years. J Bone Metab. 2024;31(3):246-9.
559. Rosen H. Denosumab for osteoporosis: UptoDate; 2025 [Available from: https://www.uptodate.com/contents/denosumab-for-osteoporosis?search=If%20denosumab%20is%20discontinued%20for%20any%20reason%2C%20an%20alternative%20therapy%20should%20be%20initiated%20to%20prevent%20rapid%20BMD%20loss%20and%20prevent%20fractures.%20Sequential%20treatment%20with%20bisphosphonates%2C%20particularly%20alendronate%2C%20is%20preferred%20and%20should%20begin%20six%20months%20after%20the%20last%20denosumab%20dose%20&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#H3285363367].
560. Rosen H, Lewiecki EM. Overview of the management of low bone mass and osteoporosis in postmenopausal women: UptoDate; 2024 [Available from: https://www.uptodate.com/contents/overview-of-the-management-of-low-bone-mass-and-osteoporosis-in-postmenopausal-women?search=A%20change%20in%20BMD%20is%20deemed%20statistically%20significant%20only%20if%20it%20exceeds%20the%20least%20significant%20change%20%28LSC%29%20for%20the%20specific%20densitometer%20used.%20If%20the%20LSC%20is%20unavailable%2C%20a%20threshold%20difference%20of%20%E2%89%A5%205%25%20has%20been%20suggested%20as%20an%20alternative&source=search_result&selectedTitle=2%7E150&usage_type=default&display_rank=2].
561. Alblazi K, Nabil S, Tumian NR, Yunus SSM, Ramli R. Potential role of comprehensive dental care in preventing medication related osteonecrosis of the jaw (MRONJ): a single centre study. BMC Oral Health. 2024;24(1):1291.
562. Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2019;127(2):117-35.
563. Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, et al. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. Biomed Res Int. 2018;2018:2684924.
564. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243-54.
565. da Silva AG, Vieira JG, Kunii IS, Lana JM, Lazaretti-Castro M. The effects of discontinuing long term alendronate therapy in a clinical practice setting. Arq Bras Endocrinol Metabol. 2011;55(4):272-8.
566. Eastell R, Hannon RA, Wenderoth D, Rodriguez-Moreno J, Sawicki A. Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab. 2011;96(11):3367-73.
567. Orr-Walker B, Wattie DJ, Evans MC, Reid IR. Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis. Clin Endocrinol (Oxf). 1997;46(1):87-92.
568. Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008;19(3):365-72.
569. Australian Institute of Health and Welfare. Chronic Pain in Australia. Canberra: AIHW; 2020.
570. Leung DKY, Fong APC, Wong FHC, Liu T, Wong GHY, Lum TYS. Nonpharmacological Interventions for Chronic Pain in Older Adults: A Systematic Review and Meta-Analysis. Gerontologist. 2024;64(6).
571. Therapeutic Guidelines. Pain and Analgesia Melbourne: Therapeutic Guidelines Limited; 2020 [Available from: https://www.tg.org.au/].
572. Tenni P, Gurgius M. A guide to deprescribing: opioids Tasmania: Primary Health Tasmania; 2022 [cited 2023 11 November]. Available from: https://www.primaryhealthtas.com.au/wp-content/uploads/2023/03/A-guide-to-deprescribing-opioids.pdf.
573. Langford AV SC, Lin CWC, Bero L, Blyth FM, Doctor JN, Holliday S, Jeon YH, Moullin JC, Murnion B, Nielsen S, Osman R, Penm J, Reeve E, Reid S, Wale J, Gnjidic D. Evidence-based Clinical Practice Guideline for Deprescribing OpioidAnalgesics. Sydney: The University of Sydney; 2022.
574. Yoshikawa A, Ramirez G, Smith ML, Foster M, Nabil AK, Jani SN, et al. Opioid Use and the Risk of Falls, Fall Injuries and Fractures among Older Adults: A Systematic Review and Meta-Analysis. J Gerontol A Biol Sci Med Sci. 2020;75(10):1989-95.
575. Bettinger JJ, Friedman BC. Opioids and Immunosuppression: Clinical Evidence, Mechanisms of Action, and Potential Therapies. Palliat Med Rep. 2024;5(1):70-80.
576. Bannister K. Opioid-induced hyperalgesia: where are we now? Curr Opin Support Palliat Care. 2015;9(2):116-21.
577. Virnes RE, Tiihonen M, Karttunen N, van Poelgeest EP, van der Velde N, Hartikainen S. Opioids and Falls Risk in Older Adults: A Narrative Review. Drugs Aging. 2022;39(3):199-207.
578. NPS MedicineWise. Lowering your opioid dose: NPS MedicineWise; 2020 [Available from: https://www.nps.org.au/assets/NPS-MedicineWise-Lowering-your-opioid-dose.pdf].
579. Garland EL, Brintz CE, Hanley AW, Roseen EJ, Atchley RM, Gaylord SA, et al. Mind-Body Therapies for Opioid-Treated Pain: A Systematic Review and Meta-analysis. JAMA Intern Med. 2020;180(1):91-105.
580. NPS MedicineWise. 5 steps to tapering opioids for patients with chronic non-cancer pain: NPS MedicineWise; 2020 [Available from: https://www.nps.org.au/news/5-steps-to-tapering-opioids].
581. Pisansky AJB, Berna C, Rathmell JP. Opioid tapering for patients with chronic pain 2025 [Available from: https://www.uptodate.com/contents/opioid-tapering-for-patients-with-chronic-pain?search=opiod%20tapering&source=search_result&selectedTitle=1%7E27&usage_type=default&display_rank=1].
582. Chu LF, Clark DJ, Angst MS. Opioid Tolerance and Hyperalgesia in Chronic Pain Patients After One Month of Oral Morphine Therapy: A Preliminary Prospective Study. J Pain. 2006;7(1):43-8.
583. Kawai S, Sobajima S, Jinnouchi M, Nakano H, Ohtani H, Sakata M, et al. Efficacy and Safety of Tramadol Hydrochloride Twice-Daily Sustained-Release Bilayer Tablets with an Immediate-Release Component for Chronic Pain Associated with Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled, Treatment-Withdrawal Study. Clin Drug Investig. 2022;42(5):403-16.
584. Vu LC, Piccenna L, Kwan P, O'Brien TJ. New-onset epilepsy in the elderly. Br J Clin Pharmacol. 2018;84(10):2208-17.
585. Golyala A, Kwan P. Drug development for refractory epilepsy: The past 25 years and beyond. Seizure. 2017;44:147-56.
586. Laue-Gizzi H. Discontinuation of antiepileptic drugs in adults with epilepsy. Aust Prescr. 2021;44(2):53-6.
587. Terman SW, Lamberink HJ, Braun KPJ. Deprescribing in Epilepsy: Do No Harm. JAMA Neurol. 2020;77(6):673-4.
588. Dunbabin D. A guide to deprescribing: antiepileptic drugs Tasmania: Primary Health Tasmania; 2022 [cited 2023 11 November]. Available from: https://www.primaryhealthtas.com.au/wp-content/uploads/2023/03/A-guide-to-deprescribing-antiepileptic-drugs.pdf.
589. Wong YS, Wu CS, Ong CT. Discontinuation of preventive antiepileptic drugs in patients with intracerebral hemorrhage. BMC Neurol. 2021;21(1):150.
590. Mathieson S, Maher CG, McLachlan AJ, Latimer J, Koes BW, Hancock MJ, et al. Trial of Pregabalin for Acute and Chronic Sciatica. N Engl J Med. 2017;376(12):1111-20.
591. Zhang J, Yan R, Cui Y, Su D, Feng T. Treatment for essential tremor: a systematic review and Bayesian Model-based Network Meta-analysis of RCTs. eClinicalMedicine. 2024;77.
592. Kilpatrick CJ. Withdrawal of antiepileptic drugs in seizure-free adults. Australian prescriber. 2004;27(5):114-7.
593. Lamberink HJ, Otte WM, Geerts AT, Pavlovic M, Ramos-Lizana J, Marson AG, et al. Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis. Lancet Neurol. 2017;16(7):523-31.
594. Therapeutic Guidelines. Neurology: epilepsy and seizures Melbourne: Therapeutic Guidelines Limited; 2020 [Available from: https://www.tg.org.au/].
595. Callaghan B, Schlesinger M, Rodemer W, Pollard J, Hesdorffer D, Allen Hauser W, et al. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia. 2011;52(3):619-26.
596. Sirven J. Approach to the discontinuation of antiseizure medications: Uptodate; 2025 [Available from: https://www.uptodate.com/contents/approach-to-the-discontinuation-of-antiseizure-medications?search=For%20individuals%20who%20have%20been%20seizure-free%20for%20at%20least%20two%20years%2C%20deprescribing%20antiepileptic%20medications&topicRef=2225&source=related_link].
597. Austroads. Assessing Fitness to Drive 2025 [Available from: https://austroads.gov.au/publications/assessing-fitness-to-drive/ap-g56/neurological-conditions/seizures-and-epilepsy].
598. Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010;8(3):254-67.
599. Tariot PN, Jakimovich LJ, Erb R, Cox C, Lanning B, Irvine C, et al. Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia. J Clin Psychiatry. 1999;60(10):684-9.
600. Gingras MA, Dubé R, Williams J, Shih J, Lieu A, Morin T, et al. Direct-to-Consumer Educational Brochures to Promote Gabapentinoid Deprescribing in Older Adults. JAMA Intern Med. 2024;184(11):1386-8.
601. Australian Medicines Handbook [Online]. Adelaide: Australian Medicines Handbook Pty Ltd; 2025 [updated July 2023. Available from: https://amhonline.amh.net.au/.
602. Wu J, Lim E-C, Nadkarni NV, Tan E-K, Kumar PM. The impact of levodopa therapy-induced complications on quality of life in Parkinson’s disease patients in Singapore. Sci Rep. 2019;9(1):9248.
603. Nanayakkara B, Di Michiel J, Yee B. Restless legs syndrome. Aust J Gen Pract. 2023;52:615-21.
604. Silber MH, Buchfuhrer MJ, Earley CJ, Koo BB, Manconi M, Winkelman JW, et al. The Management of Restless Legs Syndrome: An Updated Algorithm. Mayo Clin Proc. 2021;96(7):1921-37.
605. Haasum Y, Fastbom J, Johnell K. Use of Fall-Risk Inducing Drugs in Patients Using Anti-Parkinson Drugs (APD): A Swedish Register-Based Study. PLoS One. 2016;11(8):e0161246.
606. Liu Z, Su D, Zhou J, Wang X, Wang Z, Yang Y, et al. Acute effect of levodopa on orthostatic hypotension and its association with motor responsiveness in Parkinson's disease: Results of acute levodopa challenge test. Parkinsonism Relat Disord. 2023;115:105860.
607. Ataide M, Franco CM, Lins OG. Daytime sleepiness in Parkinson's disease: perception, influence of drugs, and mood disorder. Sleep Disord. 2014;2014:939713.
608. Scanga A, Lafontaine A-L, Kaminska M. An overview of the effects of levodopa and dopaminergic agonists on sleep disorders in Parkinson’s disease. J Clin Sleep Med. 2023;19(6):1133-44.
609. Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Mov Disord. 2000;15(3):485-9.
610. Tse W, Frisina PG, Hälbig TD, Gracies JM, Liang L, Tarshish C, et al. The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism. J Am Med Dir Assoc. 2008;9(9):670-5.
611. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306(12):1359-69.
612. Rogowska M, Thornton M, Creese B, Velayudhan L, Aarsland D, Ballard C, et al. Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update. Drugs Aging. 2023;40(1):21-32.
613. Mühlbauer V, Möhler R, Dichter MN, Zuidema SU, Köpke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2021;12(12):Cd013304.
614. Burns K, Casey AN, Brodaty H. A Clinician’s BPSD Guide 2023: Understanding and helping people experiencing changed behaviours and psychological symptoms associated with dementia Sydney: Centre for Healthy Brain Ageing (CHeBA), University of New South Wales; 2023 [Available from: https://www.cheba.unsw.edu.au/sites/cheba2/files/page/BPSD%20Guide%202023.pdf].
615. Therapeutic Guidelines. Dementia Melbourne: Therapeutic Guidelines Limited; 2025 [Available from: https://www.tg.org.au/].
616. Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229-45.
617. Yoshida K, Roberts R, Suzuki T, Lebowitz B, Reeves S, Howard R, et al. Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data. Am J Geriatr Psychiatry. 2017;25(7):708-16.
618. Bessey LJ, Walaszek A. Management of Behavioral and Psychological Symptoms of Dementia. Curr Psychiatry Rep. 2019;21(8):66.
619. Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus. Int Psychogeriatr. 2019;31(1):83-90.
620. NPS MedicineWise. Management of behavioural and psychological symptoms of dementia Australia: NPS MedicineWise; No date [Available from: https://www.nps.org.au/assets/Implementing-non-pharmacological-interventions-for-BPSD.pdf].
621. Scales K, Zimmerman S, Miller SJ. Evidence-Based Nonpharmacological Practices to Address Behavioral and Psychological Symptoms of Dementia. The Gerontologist. 2018;58(suppl_1):S88-S102.
622. Bell S, Bhat R, Brennan S, Clark M, Corlis M, Etherton-Beer C, Field S, Gilmartin-Thomas J, Haines T, Hilmer S, Jack L, Kitson A, Kourbelis C, Kurrle S, Logiudice D, Macfarlane S, Nguyen T, Page A, Pond D, Porock D, Quirke T, Srikanth V, Stafford A, Thompson J, Tan E, Wesson J (Guideline Development Group). Clinical Practice Guidelines for the Appropriate Use of Psychotropic Medications in People Living with Dementia and in Residential Aged Care: Summary of Recommendations and Good Practice Statements. Parkville: Monash University 2022 [Available from: https://www.monash.edu/__data/assets/pdf_file/0005/3657128/240424_Clinical-Pracitcie-Guidelines-for-the-Appropriate-Use-of-Psychotorpic-Medications-in-People-Living-with-Dementia-and-in-Residential-Aged-Care.pdf].
623. NSW Therapeutic Advisory Group. Deprescribing guide for antipsychotics for treatment of behavioural and psychological symptoms of dementia Sydney: NSW Therapeutic Advisory Group Inc.; 2018 [Available from: https://www.nswtag.org.au/deprescribing-tools/].
624. Koponen M, Rajamaki B, Lavikainen P, Bell JS, Taipale H, Tanskanen A, et al. Antipsychotic Use and Risk of Stroke Among Community-Dwelling People With Alzheimer’s Disease. J Am Med Dir Assoc. 2022;23(6):1059-65.e4.
625. Ralph SJ, Espinet AJ. Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care. J Alzheimers Dis Rep. 2018;2(1):1-26.
626. Liu BM, Kouladjian O'Donnell L, Redston MR, Fujita K, Thillainadesan J, Gnjidic D, et al. Association of the Drug Burden Index (DBI) exposure with outcomes: A systematic review. J Am Geriatr Soc. 2024;72(2):589-603.
627. Therapeutic Guidelines. Overview of anxiety and associated disorders Melbourne: Therapeutic Guidelines Limited; 2021 [Available from: https://www.tg.org.au/].
628. Azermai M, Petrovic M, Engelborghs S, Elseviers MM, Van der Mussele S, Debruyne H, et al. The effects of abrupt antipsychotic discontinuation in cognitively impaired older persons: a pilot study. Aging Ment Health. 2013;17(1):125-32.
629. Bach LL, Lazzaretto DL, Young CF, Lofholm PW. Improving nursing home compliance via revised antipsychotic use survey tool. Consult Pharm. 2017;32(4):228-38.
630. Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med. 2008;5(4):e76.
631. Ballard CG, Thomas A, Fossey J, Lee L, Jacoby R, Lana MM, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry. 2004;65(1):114-9.
632. Bergh S, Engedal K. The withdrawal of antipsychotics and antidepressants from patients with dementia and BPSD living in nursing homes: an open pilot study. Int J Geriatr Psychiatry. 2008;23(8):877-9.
633. Bridges-Parlet S, Knopman D, Steffes S. Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study. J Geriatr Psychiatry Neurol. 1997;10(3):119-26.
634. Brodaty H, Aerts L, Harrison F, Jessop T, Cations M, Chenoweth L, et al. Antipsychotic Deprescription for Older Adults in Long-term Care: The HALT Study. J Am Med Dir Assoc. 2018;19(7):592-600.e7.
635. Cohen-Mansfield J, Lipson S, Werner P, Billig N, Taylor L, Woosley R. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med. 1999;159(15):1733-40.
636. Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med. 2012;367(16):1497-507.
637. Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord. 2005;20(1):104-5.
638. Hortwitz GJ, Tariot PN, Mead K, Cox C. Discontinuation of Antipsychotics in Nursing Home Patients With Dementia. Am J Geriatr Psychiatry. 1995;3(4):290-9.
639. Ruths S, Straand J, Nygaard HA, Aarsland D. Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--the Bergen District Nursing Home Study (BEDNURS). Int J Geriatr Psychiatry. 2008;23(9):889-95.
640. Somani SK. Dyskinesias Secondary to Gradual Neuroleptic Drug Withdrawal in Elderly Nursing Home Residents. Am J Geriatr Pharmacother. 1996;11:37-51.
641. Thapa PB, Meador KG, Gideon P, Fought RL, Ray WA. Effects of antipsychotic withdrawal in elderly nursing home residents. J Am Geriatr Soc. 1994;42(3):280-6.
642. van Reekum R, Clarke D, Conn D, Herrmann N, Eryavec G, Cohen T, et al. A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int Psychogeriatr. 2002;14(2):197-210.
643. Westbury JL, Gee P, Ling T, Brown DT, Franks KH, Bindoff I, et al. RedUSe: reducing antipsychotic and benzodiazepine prescribing in residential aged care facilities. Med J Aust. 2018;208(9):398-403.
644. Ruths S, Straand J, Nygaard HA, Bjorvatn B, Pallesen S. Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. The Bergen District Nursing Home Study. J Am Geriatr Soc. 2004;52(10):1737-43.
645. Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. Int J Geriatr Psychiatry. 2011;26(9):937-43.
646. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151-7.
647. Bravo-Jose P, Saez-Lleo CI, Peris-Marti JF. Deprescribing antipsychotics in long term care patients with dementia. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2019;43(4):140-5.
648. NSW Therapeutic Advisory Group. Deprescribing guide for benzodiazepines and Z drugs Sydney: NSW Therapeutic Advisory Group Inc.; 2018 [Available from: https://www.nswtag.org.au/deprescribing-tools/].
649. Gonzalez-Chica D, Begum M, Bernardo C, Hoon E, Sweetman A, Stocks N. Trends and patterns of benzodiazepines and Z-drugs prescriptions in Australian general practice: A national study (2011-2018). Drug Alcohol Rev. 2023;42(2):427-38.
650. Therapeutic Guidelines. Insomnia in adults Melbourne: Therapeutic Guidelines Limited; 2025 [Available from: https://www.tg.org.au/].
651. Carr F, Tian P, Chow J, Guzak J, Triscott J, Mathura P, et al. Deprescribing benzodiazepines among hospitalised older adults: quality improvement initiative. BMJ OPEN QUALITY. 2019;8(3).
652. Chae S, Lee E, Lindenberg J, Shen K, Anderson TS. Evaluation of a benzodiazepine deprescribing quality improvement initiative for older adults in primary care. J Am Geriatr Soc. 2024;72(4):1234-41.
653. da Silva LGR, da Silva Pinto AW, de Queiroz WE, Coelho CC, Blatt CR, Oliveira MG, et al. Deprescribing clonazepam in primary care older patients: a feasibility study. Int J Clin Pharm. 2022;44(2):489-98.
654. Del Giorno R, Greco A, Zasa A, Clivio L, Pironi M, Ceschi A, et al. Combining prescription monitoring, benchmarking, and educational interventions to reduce benzodiazepine prescriptions among internal medicine inpatients; a multicenter before and after study in a network of Swiss Public Hospitals. Postgrad Med. 2018;130(7):627-36.
655. Fernandes M, Neves I, Oliveira J, Santos O, Aguiar P, Atalaia P, et al. Discontinuation of chronic benzodiazepine use in primary care: a nonrandomized intervention. Fam Pract. 2022;39(2):241-8.
656. Gnjidic D, Ong HMM, Leung C, Jansen J, Reeve E. The impact of in hospital patient-education intervention on older people's attitudes and intention to have their benzodiazepines deprescribed: a feasibility study. Ther Adv Drug Saf. 2019;10:2042098618816562.
657. Habraken H, Soenen K, Blondeel L, Van Elsen J, Bourda J, Coppens E, et al. Gradual withdrawal from benzodiazepines in residents of homes for the elderly: experience and suggestions for future research. Eur J Clin Pharmacol. 1997;51(5):355-8.
658. Javelot H, Marquis A, Antoine-Bernard E, Grandidier J, Weiner L, Javelot T, et al. Benzodiazepines withdrawal: Initial outcomes and long-term impact on falls in a French nursing home. Pharmacy. 2018;6(2):30.
659. Mendes MA, Smith JP, Marin JK, Bounthavong M, Lau MK, Miranda JL, et al. Reducing Benzodiazepine Prescribing in Older Veterans: A Direct-to-Consumer Educational Brochure. Fed Pract. 2018;35(9):36-43.
660. Navy HJ, Weffald L, Delate T, Patel RJ, Dugan JP. Clinical Pharmacist Intervention to Engage Older Adults in Reducing Use of Alprazolam. Consult Pharm. 2018;33(12):711-22.
661. Salzman C, Fisher J, Nobel K, Glassman R, Wolfson A, Kelley M. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry. 1992;7(2):89-93.
662. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890-8.
663. Allary A, Proulx-Tremblay V, Bélanger C, Hudon C, O'Connor K, Roberge P, et al. Long-term effects of benzodiazepine discontinuation among older adults: potential improvements on depressive symptoms. Aging Ment Health. 2024;28(12):1625-33.
664. Mookerjee N, Schmalbach N, Antinori G, Thampi S, Windle-Puente D, Gilligan A, et al. Comorbidities and Risk Factors Associated With Insomnia in the Elderly Population. J Prim Care Community Health. 2023;14:21501319231168721.
665. Li J, Vitiello MV, Gooneratne NS. Sleep in Normal Aging. Sleep Med Clin. 2018;13(1):1-11.
666. Woods A, Begum M, Gonzalez-Chica D, Bernardo C, Hoon E, Stocks N. Long-term benzodiazepines and z-drug prescribing in Australian general practice between 2011 and 2018: A national study. Pharmacol Res Perspect. 2022;10(1):e00896.
667. Jorm AF, Grayson D, Creasey H, Waite L, Broe GA. Long-term benzodiazepine use by elderly people living in the community. Aust N Z J Public Health. 2000;24(1):7-10.
668. Patel D, Steinberg J, Patel P. Insomnia in the Elderly: A Review. J Clin Sleep Med. 2018;14(6):1017-24.
669. Chen WC, Wang XY. Longitudinal associations between sleep duration and cognitive impairment in Chinese elderly. Front Aging Neurosci. 2022;14:1037650.
670. Wu X, Ebihara S. Associations between sleep parameters and falls among older adults with and without cardiovascular disease: Evidence from the China Health and Retirement Longitudinal Study (CHARLS). Geriatrics & Gerontology International. 2025;25(1):38-47.
671. Oliveira RL, Freitas RL, Duarte YAO, Santos JLF, Bof de Andrade F. Longitudinal association of sleep quality with physical performance measures: SABE cohort study, Brazil. Public Health. 2024;235:56-62.
672. Tiller JW. The management of insomnia: an update. Aust Prescr. 2003;26:78-81.
673. Kuo C-L, Chien IC, Lin C-H. Trends, correlates, and disease patterns of sedative-hypnotic use among elderly persons in Taiwan. BMC Psychiatry. 2022;22(1):316.
674. Xu C, Leung JCN, Shi J, Lum DH, Lai FTT. Sedative-hypnotics and osteoporotic fractures: A systematic review of observational studies with over six million individuals. Sleep Med Rev. 2024;73:101866.
675. Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169.
676. Bourgeois J, Elseviers MM, Van Bortel L, Petrovic M, Vander Stichele RH. Feasibility of discontinuing chronic benzodiazepine use in nursing home residents: a pilot study. Eur J Clin Pharmacol. 2014;70(10):1251-60.
677. Curran HV, Collins R, Fletcher S, Kee SC, Woods B, Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med. 2003;33(7):1223-37.
678. Fixen DR, Farro SA, Shanbhag P, Parnes BL, Vejar MV. Multidisciplinary Approach to Deprescribing Sedative-Hypnotic Medications in Geriatric Primary Care. J Prim Care Community Health. 2022;13:21501319221103416.
679. Gemelli MG, Yockel K, Hohmeier KC. Evaluating the Impact of Pharmacists on Reducing Use of Sedative/Hypnotics for Treatment of Insomnia in Long-Term Care Facility Residents. Consult Pharm. 2016;31(11):650-7.
680. Kosto A, Lev D, Reiss N, Meged-Book T, Press Y. Discontinuation of benzodiazepines and Z-drugs in hospitalised population at the age of 60 and above. An open-label randomized controlled trial. Int J Geriatr Psychiatry. 2023;38(10):e6012.
681. Kuntz JL, Kouch L, Christian D, Hu W, Peterson PL. Patient Education and Pharmacist Consultation Influence on Nonbenzodiazepine Sedative Medication Deprescribing Success for Older Adults. Perm J. 2019;23:18-161.
682. Lui E, Wintemute K, Muraca M, Truong C, Ha R, Choe AKB, et al. Pharmacist-led sedative-hypnotic deprescribing in team-based primary care practice. Can Pharm J (Ott). 2021;154(4):278-84.
683. Petrovic M, Pevernagie D, Mariman A, Van Maele G, Afschrift M. Fast withdrawal from benzodiazepines in geriatric inpatients: a randomised double-blind, placebo-controlled trial. Eur J Clin Pharmacol. 2002;57(11):759-64.
684. Puustinen J, Lähteenmäki R, Polo-Kantola P, Salo P, Vahlberg T, Lyles A, et al. Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. Eur J Clin Pharmacol. 2014;70(3):319-29.
685. Ragan AP, Aikens GB, Bounthavong M, Brittain K, Mirk A. Academic Detailing to Reduce Sedative-Hypnotic Prescribing in Older Veterans. J Pharm Pract. 2021;32(2):287-94.
686. Tabloski PA, Cooke KM, Thoman EB. A procedure for withdrawal of sleep medication in elderly women who have been long-term users. J Gerontol Nurs. 1998;24(9):20-8; quiz 50-1.
687. Tham TC, Brown H, Taggart HM. Temazepam withdrawal in elderly hospitalized patients: a double blind randomised trial comparing abrupt versus gradual withdrawal. Ir J Med Sci. 1989;158(12):294-9.
688. Tsunoda K, Uchida H, Suzuki T, Watanabe K, Yamashima T, Kashima H. Effects of discontinuing benzodiazepine-derivative hypnotics on postural sway and cognitive functions in the elderly. Int J Geriatr Psychiatry. 2010;25(12):1259-65.
689. Van der Linden L, Hias J, Liesenborghs A, Walgraeve K, Van Brantegem P, Hellemans L, et al. The impact of a pharmacist intervention on post-discharge hypnotic drug discontinuation in geriatric inpatients: a before-after study. BMC Geriatr. 2023;23(1):407.
690. Wilson MG, Lee TC, Hass A, Tannenbaum C, McDonald EG. EMPOWERing Hospitalized Older Adults to Deprescribe Sedative Hypnotics: A Pilot Study. J Am Geriatr Soc. 2018;66(6):1186-9.
691. Fung CH, Alessi C, Martin JL, Josephson K, Kierlin L, Dzierzewski JM, et al. Masked Taper With Behavioral Intervention for Discontinuation of Benzodiazepine Receptor Agonists: A Randomized Clinical Trial. JAMA Internal Medicine. 2024;184(12):1448-56.
692. Gardner DM, Turner JP, Magalhaes S, Rajda M, Murphy AL. Patient Self-Guided Interventions to Reduce Sedative Use and Improve Sleep: The YAWNS NB Randomized Clinical Trial. JAMA Psychiatry. 2024;81(12):1187-97.
693. Kuntz JL, Kouch L, Christian D, Hu W, Peterson PL. Patient Education and Pharmacist Consultation Influence on Nonbenzodiazepine Sedative Medication Deprescribing Success for Older Adults. The Permanente journal. 2019;23(9800474):18-161.
694. Peng XD, Huang CQ, Chen LJ, Lu ZC. Cognitive behavioural therapy and reminiscence techniques for the treatment of depression in the elderly: a systematic review. J Int Med Res. 2009;37(4):975-82.
695. Ferguson JM. SSRI Antidepressant Medications: Adverse Effects and Tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22-7.
696. Romdhani A, Lehmann S, Schlatter J. Discontinuation of Antidepressants in Older Adults: A Literature Review. Ther Clin Risk Manag. 2023;19:291-9.
697. Kato M, Hori H, Inoue T, Iga J, Iwata M, Inagaki T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2021;26(1):118-33.
698. Baldessarini RJ, Lau WK, Sim J, Sum MY, Sim K. Duration of initial antidepressant treatment and subsequent relapse of major depression. J Clin Psychopharmacol. 2015;35(1):75-6.
699. Lam RW, Kennedy SH, Adams C, Bahji A, Beaulieu S, Bhat V, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes. Can J Psychiatry. 2024;69(9):641-87.
700. Mangin D. Taper MD: Antidepressants No date [Available from: https://tapermd.com/tapering-resources/antidepressants/].
701. Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R, et al. Maintenance or Discontinuation of Antidepressants in Primary Care. N Engl J Med. 2021;385(14):1257-67.
702. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry. 2019;6(6):538-46.
703. Wallis KA, Donald M, Horowitz M, Moncrieff J, Ware RS, Byrnes J, et al. RELEASE (REdressing Long-tErm Antidepressant uSE): protocol for a 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1 in general practice. Trials. 2023;24(1):615.
704. Bergh S, Selbæk G, Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. BMJ. 2012;344:e1566.
705. Fahy S, Lawlor BA. Discontinuation of lithium augmentation in an elderly cohort. Int J Geriatr Psychiatry. 2001;16(10):1004-9.
706. Flint AJ, Rifat SL. Recurrence of first-episode geriatric depression after discontinuation of maintenance antidepressants. Am J Psychiatry. 1999;156(6):943-5.
707. Hardy BG, Shulman KI, Zucchero C. Gradual discontinuation of lithium augmentation in elderly patients with unipolar depression. J Clin Psychopharmacol. 1997;17(1):22-6.
708. Lindström K, Ekedahl A, Carlsten A, Mårtensson J, Mölstad S. Can selective serotonin inhibitor drugs in elderly patients in nursing homes be reduced? Scand J Prim Health Care. 2007;25(1):3-8.
709. Ulfvarson J, Adami J, Wredling R, Kjellman B, Reilly M, von Bahr C. Controlled withdrawal of selective serotonin reuptake inhibitor drugs in elderly patients in nursing homes with no indication of depression. Eur J Clin Pharmacol. 2003;59(10):735-40.
710. Australian Institute of Health and Welfare. Dementia in Australia Canberra: AIHW; 2024 [Available from: https://www.aihw.gov.au/reports/dementia/dementia-in-aus/contents/health-services-used-by-people-with-dementia/prescriptions-for-dementia-specific-medications].
711. Waite LM. New and emerging drug therapies for Alzheimer disease. Australian Prescriber. 2024;47(3):75-9.
712. Seibert M, Mühlbauer V, Holbrook J, Voigt-Radloff S, Brefka S, Dallmeier D, et al. Efficacy and safety of pharmacotherapy for Alzheimer's disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials. Alzheimers Res Ther. 2021;13(1):131.
713. Parsons C, Lim WY, Loy C, McGuinness B, Passmore P, Ward SA, et al. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database Syst Rev. 2021;2(2):Cd009081.
714. Kim Y, Kang DW, Kim GH, Kim KW, Kim HJ, Na S, et al. Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine. Dement Neurocogn Disord. 2025;24(1):1-23.
715. García-García R, Calleja-Hernández M. Discontinuation of cholinesterase inhibitor treatment in institutionalised patients with advanced dementia. Eur J Hosp Pharm. 2022;29(3):145-50.
716. Gaudig M, Richarz U, Han J, Van Baelen B, Schäuble B. Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. Curr Alzheimer Res. 2011;8(7):771-80.
717. Herrmann N, O'Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, et al. A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease. J Am Med Dir Assoc. 2016;17(2):142-7.
718. Minett TS, Thomas A, Wilkinson LM, Daniel SL, Sanders J, Richardson J, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003;18(11):988-93.
719. Moo LR, Martinez E, Padala K, Dunay MA, Scali RR, Chen S, et al. Unexpected Findings During Double-blind Discontinuation of Acetylcholinesterase Inhibitor Medications. Clin Ther. 2021;43(6):942-52.
720. Scarpini E, Bruno G, Zappalà G, Adami M, Richarz U, Gaudig M, et al. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. J Alzheimers Dis. 2011;26(2):211-20.
721. Morehead S, Dunbabin D. A guide to deprescribing: inhaled corticosteroids Tasmania: Primary Health Tasmania; 2022 [cited 2023 11 November]. Available from: https://www.primaryhealthtas.com.au/wp-content/uploads/2023/03/A-guide-to-deprescribing-inhaled-corticosteroids.pdf.
722. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2025 Report 2025 [Available from: https://goldcopd.org/2025-gold-report/].
723. Therapeutic Guidelines. Stable chronic obstructive pulmonary disease (COPD) Melbourne: Therapeutic Guidelines Limited; 2025 [Available from: https://www.tg.org.au/].
724. Global Initiative for Asthma. Summary Guide for Asthma Management and Prevention for Adults, Adolescents and Children 6-11 Years [Online]. Melbourne: National Asthma Council Australia; 2024 [Available from: https://ginasthma.org/reports/].
725. National Asthma Council Australia. Australian Asthma Handbook [Online]. Melbourne: National Asthma Council Australia; 2022 [Available from: https://www.asthmahandbook.org.au/].
726. Therapeutic Guidelines. Maintenance management of asthma in adults and adolescents Melbourne: Therapeutic Guidelines Limited; 2025 [Available from: https://www.tg.org.au/].
727. Scurek M, Brat K. A narrative review of theophylline: is there still a place for an old friend? J Thorac Dis. 2024;16(5):3450-60.
728. Beasley R, Harper J, Bird G, Maijers I, Weatherall M, Pavord ID. Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology. Am J Respir Crit Care Med. 2019;199(12):1471-7.
729. Bloom CI, de Preux L, Sheikh A, Quint JK. Health and cost impact of stepping down asthma medication for UK patients, 2001-2017: A population-based observational study. PLoS Med. 2020;17(7):e1003145.
730. Reddel HK, Foxley GJ, Davis SR. How to step down asthma preventer treatment in patients with well-controlled asthma - more is not always better. Aust Prescr. 2022;45(4):125-9.
731. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-73.
732. Adams SG, Anzueto A, Briggs DD, Jr., Leimer I, Kesten S. Evaluation of withdrawal of maintenance tiotropium in COPD. Respir Med. 2009;103(10):1415-20.
733. Borrill Z, Roy K, Kolsum U, Southworth T, Vestbo J, Singh D. Seretide withdrawal increases airway inflammation in moderate COPD patients. Eur J Clin Pharmacol. 2009;65(11):1165-6.
734. Choudhury AB, Dawson CM, Kilvington HE, Eldridge S, James WY, Wedzicha JA, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res. 2007;8(1):93.
735. Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med. 1999;93(3):161-6.
736. O'Brien A, Russo-Magno P, Karki A, Hiranniramol S, Hardin M, Kaszuba M, et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med. 2001;164(3):365-71.
737. Patel S, Dickinson S, Morris K, Ashdown HF, Chalmers JD. A descriptive cohort study of withdrawal from inhaled corticosteroids in COPD patients. NPJ Prim Care Respir Med. 2022;32(1):25.
738. Steeves ME, Runeberg HA, Johnson SR, Kelly KC. Discontinuation Schedule of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease. Fed Pract. 2023;40(12):398-403.
739. Therapeutic Guidelines. Conjunctivitis Melbourne: Therapeutic Guidelines Limited; 2019 [Available from: https://www.tg.org.au/].
740. Abe RY, Diniz-Filho A, Costa VP, Gracitelli CPB, Baig S, Medeiros FA. The Impact of Location of Progressive Visual Field Loss on Longitudinal Changes in Quality of Life of Patients with Glaucoma. Ophthalmology. 2016;123(3):552-7.
741. Australian Institute of Health and Welfare. Vision problems in older Australians. Canberra: AIHW; 2005.
742. Jak X, Jackson S, Naunton M, Wechsler D. A guide to deprescribing: glaucoma eye drops Tasmania: Primary Health Tasmania; 2022 [cited 2023 11 November]. Available from: https://www.primaryhealthtas.com.au/wp-content/uploads/2023/03/A-guide-to-deprescribing-glaucoma-eye-drops.pdf.
743. Bedrood S, Berdahl J, Sheybani A, Singh IP. Alternatives to Topical Glaucoma Medication for Glaucoma Management. Clin Ophthalmol. 2023;17:3899-913.
744. Diaconita V, Quinn M, Jamal D, Dishan B, Malvankar-Mehta MS, Hutnik C. Washout Duration of Prostaglandin Analogues: A Systematic Review and Meta-analysis. J Ophthalmol. 2018;2018:3190684.
745. de Paiva CS. Effects of Aging in Dry Eye. Int Ophthalmol Clin. 2017;57(2):47-64.
746. Aljeaidi M, Keen C, Bell JS, Cooper T, Robson L, Tan ECK. Dry Eyes, Ocular Lubricants, and Use of Systemic Medications Known or Suspected to Cause Dry Eyes in Residents of Aged Care Services. Int J Environ Res Public Health. 2020;17(15).
747. Chan CC, Crowston JG, Tan R, Marin M, Charles S. Burden of Ocular Surface Disease in Patients With Glaucoma From Australia. Asia Pac J Ophthalmol (Phila). 2013;2(2):79-87.